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ABSTRACT 	  	  
In this thesis I report my investigations on the role of Numb, a known cell fate 
determinant in regulating Stem Cell homeostasis and in the pathogenesis of human 
and mouse breast cancer. I have investigated the characterization of the biological 
and molecular features of Numb KO murine breast model in comparison with Numb 
deficient human breast cells model. I exploited an in vitro system (the mammosphere 
assay) to propagate and enrich breast SCs, in combination with a cell membrane 
labeling system (PKH-assay) to purify SCs. 
The absence of Numb in both murine and human models helped to clarify the role of 
this “fate determinant” starting from the SC first mitotic division in vitro up to the in 
vivo tumorigenesis and related Numb reconstitution consequences. 
Through the comparison of the self-renewal properties of normal and cancer SCs, 
both in terms of proliferative cell fate and Numb partitioning, and the study of the 
molecular mechanisms underlying abnormal growth properties, functional 
attenuation and pharmacological restoration of signaling pathways in mammary 
CSCs, I have attempted to answer the open questions regarding the role of SCs in 
cancer development and maintenance, focusing the attention on a first possible 
direct evidence for cancer SC targeted therapy.  
	   6	  
INTRODUCTION 
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Mammary gland structure and development 
The mammary gland has an apparently simple cytoarchitecture, a structure like that 
could be difficult to reconcile with the diversity of breast cancer phenotypes (Stingl 
and Caldas, 2007). This has led to the hypothesis that, despite its morphological 
simplicity, this structure is functionally complex and molecularly heterogeneous 
(Stingl and Caldas, 2007).  
The mammary gland is composed by two different cellular compartments: the 
epithelium which surrounded by an external layer of myoepithelial cells, and the 
stroma, also called the mammary fat pad, that is mainly composed of adipocytes, but 
also of other cell types, as well as fibroblasts, haematopoietic cells, blood vessel and 
neurons.  
The epithelium is a branched ductal system and a lobulo-alveolar compartment 
where rare resident multipotent mammary stem cells (MSCs) rule the development of 
the gland during embryogenesis, and its modifications in postnatal life (Williams and 
Daniel, 1983).  
The ducts branch into decreasingly smaller ductules that constitute the terminal 
ductal lobular units (TDLUs) also known as terminal end buds (TEBs, Fig. 1a,c black 
arrows, Fig. 2a), which are composed in turn of alveoli. Ducts and alveoli present a 
central lumen that opens to the body surface through the nipple. 
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Mammary epithelial cells represent the fundamental functional unit of the gland. The 
cellular epithelial architecture is composed of a bilayer of luminal cells surrounding 
the inner lumen and an external layer of myoepithelial and basal cells  (Daniel & 
Smith, 1999)  
The luminal epithelial cells of the alveoli undergo functional differentiation in 
pregnancy and produce milk. Basal and myoepithelial cells, whose contraction 
facilitates the milk release, surround both ducts and alveoli. The extensive system of 
ducts and alveoli is embedded by fibroblasts and adipocytes that compose the 
stroma of the mammary gland. (Hennighausen and Robinson, 2001, 2005; Smalley 
and Ashworth, 2003)  This “second” population grew its importance since the concept 
of “mammary fat pad” has been assumed. This structure has been no more 
considered as an inert supporting matrix. Indeed the mammary fat pad is a site of 
hormone action with stromal estrogen receptor (ER), a site of growth factor synthesis 
and a source of lipid as well (Hovey et al., 1999).  
The mammary gland develops in defined stages that are connected to sexual 
development and reproduction. These are embryonic, prepubertal, pubertal, 
pregnancy, lactation, and involution (Fig. 1). Epithelial and stroma cells derived 
embryologically from ectoderm and mesoderm, respectively. Embryonically, 
mammary gland development begins as an epithelial bud in the ventral surface of the 
fetus, that penetrates the mesenchyme and form a rudimental ductal system 
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connected to the body surface trough the nipple. The number and location of glands 
vary among different classes of mammals. 
In mice, five pairs of glands develop along a ventral line, whereas only one pair 
develops in the thoracic region in humans (see Materials and Methods Fig. 3 
“Diagram of Mammary Tissue”). During puberty the ducts grow and branch further so 
that, in the mature animal, the entire fat pad is filled with a complete ductal system. 
The alveolar compartment expands and matures during pregnancy, and then, during 
lactation, secretes milk. Lactation is followed by involution, a stage during which 
alveoli undergo apoptosis and remodeling to restore a simple ductal structure. 
Alveolar expansion and maturation, lactation and involution initiates with a new 
pregnancy (Hennighausen and Robinson et al., 2001, 2005; Smalley and Ashworth, 
2003). 
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Figure 1 
Stages of mouse mammary gland development 
Whole mount images of mouse mammary gland during its development. (A) Epithelial bud in 
the fetus (Arrows). (B-D) Ductal tree in newborn (B), 3 week-old (C) and adult (D) animal 
(arrow in C 
indicate a TEB). (E) Alveolar development during pregnancy. (F) Alveolar involution. 
Modified from Hennighausen and Robinson, 2001. 
 
SCs and breast development 
It has been proposed that the cells forming the epithelial compartment of the 
mammary gland are derived from mammary SCs, which have the capacity to self-
renew and give rise to progenitor cells, which are destined for either a basal or a 
luminal fate. The presence of SCs should be the basis of the profound capacity for 
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alveolar renewal in each subsequent pregnancy. It is generally thought that, in the 
mammary gland of pubertal mice, SCs reside in the TEBs, the structures at the end of 
the ducts that constitute their growing units. TEBs are composed of a mass of body 
cells surrounded by a layer of cap cells. Cap Cells are the putative SCs; they generate 
the outer side of the TEB and will differentiate in the myoepithelial, basal or luminal 
cells. The ductal lumen forms because of apoptosis occurring in the mass of 
developing body and luminal cells. TEBs disappear at the end of the puberty, when 
the mammary gland reached its full development (Smalley and Ashworth, 2003). 
 
 
Figure 2 
Structure of mammary epithelium on different stages of differentiation.  
(A) Prepubertal and pubertal mammary gland.  Ducts terminate with highly proliferative 
terminal end buds (TEBs).  
(B) Extensive ductal branching during pregnancy. Formation of alveolar structures required for 
milk production. 
(Gajewska et al., 2013) 
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Human breast cancer 
Breast cancer is one of the most common cancers and a major cause of death despite 
the significant advances in the comprehension of its pathogenesis, diagnosis and 
treatment over the last decades (Ferlay et al., 2010).  
The heterogeneity of breast cancer complicates the clinical management of patients 
and represents a major problem in the prediction of prognosis and response to 
therapy.  The molecular understanding of both inter- and intra-tumor heterogeneity 
has until recently been poor. Inter-tumor heterogeneity has long been recognized by 
histo-pathologists who, based on their microscopic observations, were able to 
identify and classify 17 different histological subtypes of breast cancer with different 
clinical behavior (Tavassoli et al., 1999). Beyond gross histological differences among 
tumors, pathologists have also been able to develop a grading system based on the 
level of differentiation, number of mitoses and nuclear pleomorphism, to classify 
tumors into different grades with different clinical behavior. For example, according 
to The Gleason System (Gleason, Mellinger 2002) tumors are classified on the base of 
their level of differentiation and grade of complexity, scoring from a G1 to a G3 class 
where a G1 represents a well differentiated, less aggressive type of tumor while a G3 
is a poorly differentiated kind, and more aggressive associated with a bad prognosis. 
Pece et al. recently demonstrated that G3 tumors differ from G1 class on the base of 
their SC content (Pece et al., 2010) arguing a possible critical involvement of SCs in 
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the determination of the molecular and pathological differences pathogenesis among 
breast tumors. According to these evidences, and to the “SC theory of cancer” (see 
later) SCs plays are the major interest of my research study.  
The Stem Cell Theory of Cancer 
SCs are a long-lived cell population responsible for tissue formation, homeostasis 
and repair. They are defined by their ability to perpetuate themselves through self-
renewal and to generate mature cells of a particular tissue through differentiation. 
Since SCs have been identified in several tissues like blood, breast, colon, lung, liver 
and brain, it seems reasonable to propose that every tissue is maintained by tissue-
specific SCs. An attractive hypothesis proposes that SCs or their direct progenies, due 
to their extended life span, are the ideal target of cell transformation, and that 
cancers are thus supported by transformed SCs, which retain the same self-renewing 
and differentiating properties of their normal counterparts (Reya et al., 2001; 
Shipitsin and Polyak, 2008). The first demonstration of the existence of a rare 
population of cancer-initiating cells came from studies performed in 1994, by the 
John Dick group in Toronto (Lapidot et al., 1994).  Their experiments led to the 
formal demonstration that, within a tumor, only specific cell subsets were able to 
generate a new tumor upon transplantation. Since the transplanted tumors showed 
the same cell heterogeneity of the original one and could be further transplanted to 
obtain tertiary tumors, these experiments also demonstrated that tumor-initiating 
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cells possess the ability to self-renew and differentiate. Thus, these rare cells share 
the same features of normal SCs and for this reason they are referred to as Cancer 
SCs (Campbell and Polyak, 2007; Visvader and Lindeman, 2008). The first report of 
cancer SCs in human breast cancer samples came in 2003 when Al-Hajj showed how 
cancer SCs highly enriched samples were able to generate breast carcinoma upon 
transplantation into the mammary tissue of NOD-SCID mice (Al-Hajj et al., 2003).  
Based on these findings, the Cancer Stem Cell Hypothesis implicates that a particular 
subset of tumorigenic cells with stem cell-like properties drives tumor initiation, 
progression and relapse.  
 
Figure 3 
Cancer stem cell hypothesis 
Cancer-causing mutations are likely to occur in normal adult stem or progenitor cells. 
These cells give rise to “Cancer Stem Cells” that can self-renew and differentiate to 
produce all the other cells of the tumor.  
Modified from Campbell and Polyak, 2007. 
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Cancer Stem Cells  
The concept of tumor has deeply changed throughout the years. At the beginning 
tumors were traditionally regarded as biologically homogenous populations of cells 
with high proliferating activity. Than with the assumption of  “Cancer Stem Cells” 
concept, the tumor has been approached as an aberrant organ initiated by a 
tumorigenic cancer cell that acquired the capacity for not-ended proliferation 
through accumulated mutations. One critical limitation to the validation of this 
concept is our poor understanding of the biological and molecular differences 
between SC and CSCs. It is still unknown whether CSCs, as compared to SCs, have 
different growth potential, life span, drug sensitivity and, more importantly, which 
are the relevant underlying molecular pathways. Well is known that this 
subpopulation of tumorigenic cells have SC properties and they are thought to drive 
and sustain growth and metastasis of spontaneously occurring tumors (Clarke and 
Fuller, 2006; Zhang and Rosen, 2006). 
CSCs have been defined on the basis of their ability to seed tumors in animal hosts, 
to self renew and to spawn differentiated offspring (Clarke et al., 2006). Accordingly, 
the representation of CSCs within a population of cancer cells can be measured by 
the number of cells that are required, at limiting dilutions, to seed new tumors. 
(Gupta et al., 2009) 
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SCs, CSCs and Non-CSCs 
There are several analogies between normal stem cells and tumorigenic cells, most 
notably as normal adult SCs, CSCs have the ability to generate more SCs (‘self-
renewal’) and to differentiate (Reya et al., 2001).  
Both of them have extensive proliferative potential and the ability to give rise 
respectively to new normal and abnormal outgrowth; both tumors and normal tissues 
are composed of heterogeneous combinations of cells, with different phenotypic 
characteristics and different proliferative potentials (Fidler et al., 1977 Nowell et al., 
1986). Since CSCs are endowed as SCs with proliferative potential, but lack in control 
on it, they can lead to the production of any cancer cell type, accounting for tumor 
heterogeneity.  
According to the cancer clonal origin concept (Fearon et al., 1987), CSCs give rise to 
phenotypically diverse progeny composed of cells with indefinite proliferative 
potential, but also non-CSCs, which are not able to self-renew and cannot 
differentiate to produce other tumor cell types. Non-CSCs are phenotypically 
heterogeneous cells that exhibit various degrees of differentiation, their presence in 
the tumor is an attempt of “process of organogenesis”, that is however aberrant and 
poorly regulated (Reya et al., 2001).  
CSCs are supposed to arise from normal stem or progenitor cells and are thought to 
persist as a small fraction of the total cells in the tumor; tumor progression is a result 
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of the expansion of these cells. According to this model, tumors can be considered 
as aberrant, hierarchically organized tissues, with cancer SCs responsible for their 
phenotypical and functional properties and their proliferation potential (Campbell and 
Polyak, 2007;Visvader and Lindeman, 2008). 
Weinberg underlines the possibility for CSCs to differentiate into non-CSCs, but also 
the reverse process must now also be considered. There is a possibility of a 
bidirectional interconvertibility, a dynamic equilibrium between CSCs and non-CSCs 
within tumors, this equilibrium may be shifted in one or another direction by 
contextual cues within the tumor microenvironment. Non-CSCs upon these 
conditions may become reprogrammed into CSCs via a process called Epithelial to 
Mesenchymal Transition (EMT), this shift could raise CSCs number up within the 
tumor (Santisteban et al., 2009). 
Several recent reports have suggested that some 25% of the cancer cells within 
certain tumors have the properties of CSCs (Kelly et al., 2007; Quintana et al., 2008) 
so CSCs are not a so rare subpopulation within tumors.  
The ratio between CSCs and non-CSCs is a critical issue in the tumor evolution. This 
proportion differs on the basis of the stage of malignant progression reached by a 
tumor (Harris et al., 2008; Chiou et al., 2008), it is no accident the tumor malignancy 
is evaluated on the degree of differentiation manifested by the cancer cells within a 
tumor (Gupta et al., 2009). 
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This assumption further charges CSCs responsibility in tumor development. A 
plausible corollary is that the selective ablation of CSCs should lead to the 
‘‘sterilization’’ of the tumor and to its cure (Cicalese et al., 2009). 
Alternatively CSCs can be eliminated by inducing their differentiation. Histone 
deacetylase (HDAC) inhibitors may have therapeutic value as “differentiation - 
inducing” agents driving the differentiation of mesenchymal-like cancer cells and 
CSCs, which could trigger apoptotic responses or chemosensitize (Singh et al., 2010). 
 
Molecular pathogenesis of breast cancer 
Breast carcinogenesis involves a series of progressive changes that accumulate in the 
stepwise acquisition, by breast epithelial cells, of the so-called “hallmarks of cancer”: 
i.e., genome instability, sustained proliferative signaling, evasion of growth 
suppressors, resistance to cell death, replicative immortality, induction of 
angiogenesis, activation of invasion and metastasis, reprogramming of energy 
metabolism, and evasion of immune destruction (Hanahan & Weinberg 2011). These 
acquired abilities, which drive and sustain cancer growth and metastasis, reflect the 
accumulation of genetic changes that are mainly categorized in two classes: 1) loss of 
function of tumor suppressor genes and 2) gain of function of oncogenes. The 
antagonistic mechanisms between oncogenes and oncosuppressors indeed finely 
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rules the multiple events controlling the entry in mitosis and the correct operation of 
this complex pathway is responsible for the cell homeostasis even when it is lost.   
An oncogene is a mutated and/or overexpressed gene (defined proto-oncogene in its 
wild-type form) that alone, or in collaboration with other changes, promotes cellular 
transformation, growth and invasion. In contrast, a tumor suppressor gene normally 
counteracts cell growth or other processes that may increase invasive and metastatic 
potential and whose loss of function promotes malignancy. In addition to protein-
coding genes, in the last decade the importance of non-coding RNAs and their 
involvement in tumorigenesis has been documented, together with their ability to 
work as oncogenes or tumor suppressor genes (Croce et al., 2008).  
 
The factors acting in tumorigenesis 
The most frequently activated and best characterized oncogenes in breast cancer 
include v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (ERBB2), 
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PI3KCA), v-
myc avian myelocytomatosis viral oncogene homolog (MYC), and cyclin D1 (CCND1). 
In contrast, the tumor suppressor protein p53 gene (TP53), the breast cancer 
susceptibility genes 1 and 2 (BRCA1 and BRCA2), the phosphatase and tensin 
homolog gene (PTEN), the E-cadherin gene (CDH1), the retinoblastoma gene (RB1) 
and members of the cyclin-dependent kinase inhibitor (CKI) family represent the 
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most frequently altered tumor suppressor genes in breast cancer. Undoubtedly, many 
more oncogenes and tumor suppressor genes contribute to breast carcinogenesis. 
Given the heterogeneity of breast cancers, a better understanding of the genetic 
lesions that drive tumorigenesis in the mammary gland, will lead to improvements in 
the clinical management of breast cancer patients. 
  
The role of p53 Tumor Suppressor and the pathogenesis of cancer 
The gene TP53 is located on 17p13.1, it has been studied for the last 30 years. The 
encoded protein p53  is a tumor suppressor and is considered  as one of the most 
important molecules in human cancer since it is the most frequently mutated tumor 
suppressor in human tumors (Levine et al., 1997). More than 50% of all cancer cases 
carry TP53 mutations. This frequency is slightly lower in breast cancer with 15 – 34% 
of cases harboring TP53 mutations (Hartmann et al., 1997). 
p53 has been defined as the “guardian of the genome” (Lane et al., 1992). The 
protein p53 acts primarily as a transcription factor, inducing the expression of genes 
involved cell cycle checkpoint activation, DNA repair, cell migration, cell metabolism, 
cellular senescence, apoptosis and autophagy in response to cellular stresses 
displaying hence a potent anti-proliferative and pro-apoptotic functions (Vogelstein 
et al., 2000). 
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When normal cells are damaged by ionizing radiation or mutagens, p53 is activated 
by phosphorylation to maintain cellular homeostasis and accumulates in the nucleus 
where it binds as a tetramer to specific sequences to activate transcription of these 
genes. One of the target genes induced by p53 is p21, an inhibitor of cyclin-
dependent kinases (CDKs) that causes cell cycle arrest. GADD45, another p53 target 
gene, is in charge of repairing damaged DNA. When repair is successful p53 is 
degraded by the action of the ubiquitin-ligase MDM2 and the cell cycle restarts. 
When GADD45 cannot repair the genome because of excessive DNA damage, p53 
trans-activates the pro-apoptotic gene BAX, which induces apoptosis (Levine et al., 
1997).  
p53 dysfunction/inactivation allows cells to survive DNA damaging insults, which 
may result in the accumulation of activating mutations in proto-oncogenes or 
inactivating mutations in tumor suppressor genes and, consequently, to malignant 
transformation. 
 
The p53-MDM2 axis 
About 50% of all tumors analyzed display mutation or loss of p53, this data puts in 
evidence the key role of p53 in tumorigenesis as tumor suppressor (Levine et al., 
1994). 
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When the cell undergoes a stress condition, p53 is activated and rule either a G1 
arrest in cell cycle or apoptosis. When the cell is in physiological condition, p53 is 
always synthetized but even rapidly degraded to maintain its basal activity controlled.  
Several mechanisms participate to both stabilize and activate p53. Its fate is decided 
by the direct competition between acetylation and ubiquitination for the same 
residues (Ito et al., 2002; Li et al., 2002). The major sites for p53 ubiquitination are 
located at its C terminus, and acetylation of these residues during times of cell stress 
serves to block protein degradation and stabilize p53 (Brooks et al., 2006) 
The MDM2 oncoprotein plays a central role in that regulatory process (Fakharzadeh 
et al., 1993). The p53-MDM2 interaction domain has been co-crystallized revealing 
that the N-terminal region of MDM2 forms a deep hydrophobic cleft in which three 
p53 amino-acid residues, Phe19, Trp23 and Leu26, deeply insert into (Kussie et al., 
1996). 
MDM2 protein level and its RNA as well fall after DNA damage, caused for example by 
UV irradiation. In these conditions Mdm2 itself can be acetylated (Wang X et al., 
2004) on residues within the RING domain. In this way Mdm2 becomes inactivated 
and leads to an increase in p53 transcriptional activity (Brooks et al., 2006; Lane et 
al., 1992). 
Vice versa, after DNA repair, to downsize p53 activity, MDM2 levels increase: as 
consequence MDM2 binds p53 in the nucleus and carries it in the cytoplasm where 
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p53 is degraded in the proteasome (Shirangi et al., 2002; Xirodimas et al., 2001; 
Bottger et al., 1997). These two proteins thus form an autoregulatory feedback loop 
in which p53 positively regulates MDM2 levels and MDM2 negatively regulates p53 
levels and activity, while in unstressed cells, both p53 and MDM2 are kept at very low 
levels (Wu et al., 1993). 
In several p53-mutated tumors, p53 is overexpressed, but MDM2 is not. That 
happens because these tumors loose this feedback and p53 is not regulated by 
MDM2 anymore (Brooks et al., 2006). 
Furthermore in some wild-type p53 tumors, the Mdm2 gene overexpression can 
block p53 function and promote the tumor growth independently of p53 (Chen et al., 
1996).  
MDM2 can be so considered as a p53 real controller mediating p53 degradation in 
unstressed cells and controlling p53 levels and activities during the stress response 
(Shirangi et al., 2002). Mediating p53 ubiquitination, MDM2 facilitates the termination 
of the stressed cellular state and thus maintains low steady-state levels of p53 in 
unstressed normal cells. (Brooks et al., 2006) 
The p53-binding site on MDM2 has a key role for the functional consequence of the 
interaction between the two proteins. The very same amino acids in p53 that contact 
MDM2 are required indeed for p53 to activate transcription (Lin et al., 1994) 
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MDM2 can so block p53 ability to act as a transcription factor, by competing with the 
transcriptional machinery for p53 interaction. In addition, there are several 
indications that MDM2 itself may play a role in cell cycle progression or 
tumorigenesis independent of its ability to inhibit the tumor suppressor functions of 
p53 (Ganguli et al., 2003). 
By the way MDM2 is not the only factor influencing p53 homeostasis, there is a third 
partner, Numb indeed, interacting with both of them. As recently demonstrated by 
Colaluca, Numb, the protein that I’m studing in my thesis, by binding the p53-MDM2 
complex can influence p53 homeostasis (Colaluca et al., 2008) since in presence of 
Numb, p53 is preserved by ubiquitination executed by MDM2; this condition is lost 
upon Numb deficiency bringing to an early decrease of p53 levels. These evidences 
support previous data edited by Pece, where G3 tumors, notably the most difficult to 
treat, resulted enriched in SC content (Pece et al., 2004) and nevertheless emerged to 
be Numb lacking in a conspicuous percentage of cases (Pece et al., 2004; Colaluca et 
al., 2008).  
This scenario strongly focuses the attention on Numb not only in relationship with 
the p53-MDM2 axis, but also with the cell fate itself. Intrigued by these evidences we 
decided to study the role of Numb in SC compartment homeostasis and its loss as 
possible crucial event in the tumorigenesis. 
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Contribution of the NUMB–HDM2–p53 axis to breast cancer 
Colaluca has recently shown how the cell-fate determinant Numb can influence the 
tumor suppressor protein p53 homeostasis. Loss of Numb in breast cancers would 
result, therefore, in both the activation of the potential oncogene Notch and the 
diminution of tumor suppression by p53 (Carter et al., 2008). 
The evidence of an axis between MDM2 and p53, but also between p53 and Numb 
suggests the existence in vivo of multiple binary complexes (NUMB–HDM2, NUMB–
p53 and HDM2–p53), or of a tricomplex NUMB–HDM2–p53 (Colaluca et al., 2008). In 
physiological conditions, Numb preserves p53 protein levels and its activity, and 
regulate p53-dependent phenotypes. 
The simultaneous presence of NUMB–HDM2–p53 together prevents the ubiquitination 
and degradation of p53. The real mechanism through which Numb preserves p53 is 
still unknown; Numb may simply intercalate between p53 and MDM2 or rather inhibit 
the conformational change that involve the p53-MDM2 complex after their 
interaction.  This last event in particular is indeed critical for ubiquitination of 
p53.(Momand et al., 1992; Haupt et al., 1997; Kubbutat et al., 1997; Carter et 
al.,2008). 
The recent identification of Numb as a protein controlling p53 levels and activity 
(Colaluca et al., 2008) leads obviously to the possibility that Numb can regulate 
cancer development. 
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Many evidences show how Numb is often loss in breast cancers, indeed one third of 
all breast tumors are Numb-deficient; the lack of Numb causes decreased p53 levels 
and both these events correlate with aggressive disease and poor prognosis 
chemoresistance (Westhoff et al., 2009). 
Colaluca demonstrated that Numb overexpression increases p53 stability and activity 
showing that Numb levels are relevant to the p53-mediated cellular responses, in 
particular in breast tumors where the loss of Numb expression is frequently detected.  
Thereby Numb might be relevant to SC homeostasis because of its influence on p53, 
than a p53/Numb signaling axis might function as a tumor suppressor pathway in 
mammary SCs: in support of that the reduction in p53 levels was caused by loss of 
Numb, throughout MDM2, while forced re-expression of Numb or silencing of MDM2 
restored normal p53. On the other hand the loss of Numb expression could 
contribute hence to malignant transformation by reducing p53 activity, Thereby 
p53/Numb axis has to be considered as an additional mechanism with possible 
involvement in tumorigenesis in breast cancer in which mutations of p53 are 
relatively infrequent if compared with the entire panel of tumors displaying p53 
mutations (Pharoah et al., 1999). Accordingly, restoring Numb expression or p53 
levels in Numb-deficient tumors should constitute an effective SC-targeted therapy.  
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The Numb-Notch axis 
The first evidences of Numb relevance in SC fate came from studies carried in 
Drosophila. In this model, Numb is membrane associated and during mitosis it 
symmetrically segregates influencing Notch repartition and function  (Cayouette & 
Raff 2002). The effects of Numb loss were previously studied indeed focusing the 
attentions on the Numb-Notch axis. (Pece et al., 2004) 
Notch is a plasma membrane receptor; it binds to a family of transmembrane ligands, 
resulting in cleavage of the receptor, translocation of the intracellular domain to the 
nucleus and activation of a number of target genes. Its function is involved in the 
control of cell fate specification and in the maintenance of the balance between 
proliferation and differentiation in development and homeostasis in many cell 
lineages (Artavanis-Tsakonas et al., 1999; Mumm and Kopan, 2000), and alterations 
in Notch signaling have been implicated in tumorigenesis (Robbins et al., 1992; 
Gallahan et al., 1996; Capobianco et al., 1997). 
Numb inhibits Notch through its N-terminal phosphotyrosine-binding domain (PTB) 
(Guo et al. 1996) in a sort of biological antagonism influencing cell development and 
homeostasis. Nevertheless Numb prevents the translocation of activated Notch to the 
nucleus inducing its ubiquitination and meanwhile controlling Notch intracellular 
domain degradation (McGill & McGlade 2003). 
Numb-mediated control on Notch is relevant to the normal mammary parenchyma 
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and its subversion contributes to human mammary carcinogenesis. This signaling is 
lost in some 50% of human mammary carcinomas, due to specific Numb 
ubiquitination and proteasomal degradation. When Numb is lost, in Numb-negative 
tumors, increased Notch signaling is observed, but it reverts to basal levels after 
enforced expression of Numb. The pharmacological inhibition of Notch has been 
proposed as possible approach to suppress Numb-negative tumors growth (Pece et 
al., 2004). 
 
Mode of division of normal SCs 
All SCs can generate identical copies of themselves but also give rise to more 
differentiated progeny by undergoing both symmetrical and asymmetrical divisions.  
An asymmetric cell division is defined as any division that gives two sister cells that 
have different fates, differences in size, morphology, gene expression pattern, or the 
number of subsequent cell divisions undergone by the two daughter cells (Horvitz 
and Herskowitz, 1992). On the other hand, a hallmark of symmetric SC division is the 
increase in the number of SCs.  
The two cells generated by asymmetric divisions differ markedly in their proliferative 
potential: the SC remains quiescent or slowly proliferates (‘‘self-renewal’’), whereas 
the progenitor cell undergoes multiple rounds of divisions before entering a 
postmitotic fully differentiated state. This mechanism ensures the production of large 
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numbers of differentiated progeny, while maintaining a relatively small pool of long-
lived SCs (Morrison and Kimble, 2006). Mammalian adult SCs, which are supposed to 
divide asymmetrically under steady-state conditions (Januschke and Gonzalez, 2008; 
Morrison and Kimble, 2006), retain the capacity to divide symmetrically expanding in 
number through rounds of symmetric self-renewing divisions, whereby each SC 
produces two new cells with identical SC fate and proliferation potential; in this way it 
is possible to refill the SC pools depleted by injury or disease (Morrison and Kimble, 
2006). 
 
Intrinsic mechanism vs extrinsic mechanism 
Cells undergoing asymmetric divisions use apical-basal or planar polarity of the 
surrounding tissue to set up an axis of polarity, this axis is used to orient the mitotic 
spindle and to polarize the distribution of specific protein determinants, responsible 
in the cell fate (intrinsic mechanism). Classic examples of asymmetric divisions that 
are controlled by an intrinsic mechanism are provided by the C.elegans zygote 
(Morrison and Kimble, 2006) and the Drosophila larval neural SCs (Neuroblasts) 
(Januschke and Gonzalez, 2008).  
Alternatively, according to the “stem niche” concept (extrinsic mechanism), the SC 
maintains the potential to self-renew because of the asymmetric placement of 
daughter cells in relation to stem cell niche external micro-environment. Only the 
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daughter cell that remains close to the niche has access to the extrinsic signals 
necessary for maintaining SC identity and the daughter cell placed away from the 
niche is exposed to signals that induce differentiation (Li and Xie, 2005). 
 
The intrinsic mechanism 
Asymmetric SC division can be obtained through regulated assembly of cell polarity 
which brings to asymmetric partitioning of cell components that determine cell fate; 
these “fate determinants” are inherited by only one of the two daughter cells 
throughout controlled segregation ruled by proteins like Par-3, Par-6, atypical PKC 
(aPKC) (Betschinger and Knoblich, 2004; Suzuki and Ohno, 2006; Goldstein and 
Macara, 2007). Asymmetric localization of PAR–aPKC complex at the apical cortex 
initiates the asymmetric partition of cell fate determinants while the regulated mitotic 
spindle orientation ensures their segregation through the cell polarity complex to one 
daughter; among the “fate determinants”, Numb plays a critical role. For example in 
undifferentiated neural progenitors, during the development of the mouse cortex, 
Numb asymmetrically accumulates to precursors destined for neurogenesis (Shen et 
al., 2002). Numb is also asymmetrically distributed to progeny of cultured satellite 
muscle cells, where it promotes myogenic differentiation of one daughter cell 
(Conboy and Rando, 2002; Shinin et al., 2006). Thus, asymmetric segregation of 
Numb may be a mechanism that control asymmetric division.  
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Interestingly, both mammalian basal epidermal progenitors (Lechler and Fuchs, 2005) 
and cortical ventricular zone neural progenitors (Chenn and McConnell, 1995) seem 
to exploit the “intrinsic mechanism” to regulate the orientation of mitotic spindles 
which relies on the cortical localization of the PAR–aPKC complex (Lechler and Fuchs, 
2005), a mechanism that also controls the asymmetric division of Drosophila and C. 
elegans SCs (Morrison and Kimble, 2006). 
Recent studies stress the importance of these “fate determinants” even for their 
influence on factors like p53 (Colaluca et al., 2008), all along considered among the 
major controllers in mitosis (Innocente et al., 1999) and in asymmetric divisions as 
well (Cicalese et al., 2009). 
 
Numb, polarity, SC division and cancer 
Polarity is defined as a structural and/or functional asymmetry (Casanova et al., 
2007). Cells like epithelial cells and neurons are intrinsically polarized in situ, 
whereas others become polarized transiently in response to external cues, for 
example, migrating cells, lymphocytes and phagocytes. Cell polarity is involved also 
in the cell fate determination throughout the asymmetric cell division, in which fate 
determinants become differentially distributed between daughter cells (reviewed by 
Suzuki & Ohno, 2006; Betschinger & Knoblich, 2004). Recently research groups 
focused their attention on Numb because of its involvement in SC asymmetric cell 
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division driven by evidences on Numb critical role emerged in Drosophila and 
vertebrates. 
 
Numb in Drosophila developmental model system  
The previous studies conducted in Drosophila put in evidence a complex pattern of 
functions played Numb. (Uemura et al., 1989). Numb is an evolutionary conserved 
membrane associated protein (Verdi et al., 1996). Its link with the membrane is 
guaranteed by the phosphotyrosine binding domain (PTB) (Li et al., 1998) and by 
several N-terminal positively charged amino acids that might interact with membrane 
phospholipids. During interphase, Numb is distributed uniformly around the plasma 
membrane. The membrane association before their asymmetric localization may be 
an example of “reduction of dimensionality”, through which a protein gets a two-
dimensional distribution in the plasma membrane rather than a three-dimensional 
diffusion in the cytoplasm. Through this mechanism the protein is quickly available 
to delocalize in the following mitotic phase (Jan et al., 1998).  
 
Role of Numb in SC division 
Since the firsts studies in Drosophila, results have put in evidence how Numb is 
involved in SC fate determination mechanisms such as the asymmetric mitotic 
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division with crucial consequences in the following daughter cells development. 
Indeed the asymmetrical partitioning of Numb during cell division of the sensory 
organ precursor (SOP) gives rise differentially to sensory neurons and other 
supporting cells of the external sense organ in the Drosophila peripheral nervous 
system (Rhyu et al., 1994). On the other hand, defects of Numb can affect the 
asymmetric division than increasing SC number; this evolves in tissue overgrowth 
bringing to brains growth to enormous size and eventually death. Loss of Numb 
function resulted in SCs offspring aberrant differentiating in the SOP, leading to the 
production of support cells without sensory neurons. Moreover Numb mutations 
typically lead to an overproliferation of neuroblasts during larval stages (Caussinus 
and Gonzalez 2005).  
These findings established in Drosophila a causal relationship among loss of polarity, 
loss of Numb, symmetric division in the neuroblast and tumorigenesis in the mutant 
neuronal tissue. Thus, asymmetric division might function as a mechanism of tumor 
suppression in the Drosophila neuroblast, and impaired fate specification during SC 
division might be one of the initial events that drive these cells into malignancy. 
Moreover impairment in asymmetric cell division and tumorigenesis occurring after 
Numb loss strongly argue a role of Numb as “fate determinant” but also as tumor 
suppressor (Pece et al., 2004; Caussinus and Gonzalez 2005; Bello et al., 2006; 
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Betschinger et al., 2006; Lee et al., 2006; Wang et al.,2009; Wang et al.,2007; 
Gonzalez et al., 2007; Castellanos et al., 2008)  
It is unclear whether there is also a direct causal relationship between loss of SC 
polarity and/or asymmetric divisions and tumor initiation even in mammals but the 
genes that control asymmetric cell divisions in Drosophila have an evolutionarily 
conserved role in the regulation of cell polarity and in tumor suppression, suggesting 
that polarity loss may contribute causally to cancer in mammals (Gonzalez et al., 
2007; Januschke and Gonzalez, 2008). 
During mitosis, Numb concentrates in the plasma membrane area overlying only one 
of the two spindle poles so acquiring a polarized distribution. Thereby Numb 
segregates into one of the two daughter cells during cytokinesis (Rhyu et al., 1994). 
Numb unequal segregation during the asymmetric cell divisions (intrinsic mechanism) 
is directed by the conserved Partition Defective Complex (Par) (Ohno et al., 2001; 
Suzuki and Ohno 2006) containing Par3, Par6 and by atypical protein kinase C (aPKC) 
(Henrique and Schweisguth, 2003; Macara et al., 2004). Three classes of Par proteins 
can be distinguished: the serine/ threonine kinase PAR-1 (Guo and Kemphues 1995) 
and the RING finger protein PAR-2 (Boyd et al. 1996) accumulate on the posterior cell 
cortex ruling the epithelial apical–basal polarity, whereas the anterior cell cortex is 
occupied by the PSD95/Dlg/ZO1 (PDZ) domain proteins PAR-3, PAR-6 and aPKC. 
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In mammals Numb binds to membranes through its N terminus, this plasma 
membrane affinity is regulated by Numb phosphorylation status (Knoblich et al. 
1997) which is dynamically regulated by G protein coupled receptors and by direct 
activation of PKC. Both mammalian and Drosophila Numb interact with, and are 
substrates for aPKC throughout phosphorylation on specific serine residues. Numb 
indeed has a region containing at least 12 serines between amino acids 218 and 366. 
These residues are putative PKC phosphorylation sites. The phosphorylation on these 
residues neutralizes the charges and prevents membrane localization of Numb (Smith 
et al., 2007) (Dho et al., 2006). 
Through this mechanism, PKC regulates Numb movement between the cell cortex 
and the cytosol in mammalian cells (Dho et al., 2006). When this pathway is activated, 
Numb localizes to the basolateral membrane and is excluded from the apical domain, 
which accumulates aPKC. Numb phosphorylation by aPKC serves as a conserved 
mechanism to regulate its polarized distribution during asymmetric cell divisions 
(Smith et al., 2007 Wirtz-Peitz et al. 2008). 
 
Mode of division in CSCs 
As previously demonstrated (Reya et al., 2001), there are several analogies between 
SCs cells and CSCs, but the responsible for CSCs tumorigenic potential could be 
found reasonably among their differences. 
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WT mammary SCs undergo limited rounds of mitotic division rapidly losing self-
renewal potential in culture, before entering a post-mitotic fully differentiated state 
(progenitors cells) (Daniel et al., 1968). CSCs are nearly immortal and their potential 
be serially transplanted is virtually unlimited. CSCs by dividing asymmetrically, 
guarantee the self-renewal division; this strategy allows CSCs number retain and 
differentiation but leaving them unable to expand in number. Therefore, in order to 
expand their pool, CSCs must perform both asymmetric and symmetric divisions; the 
latter generates two new daughters with the same CSC fate (Morrison and Kimble, 
2006). 
By dividing symmetrically and asymmetrically they can increase their number 
producing only identical CSC daughters in some divisions and only identical 
differentiated daughters in others. This combined strategy brings to a differentiated 
progeny, hence CSCs maintain tumor cell heterogeneity and lead to the continuous 
expansion of the tumor mass. The mechanism responsible in this switch is still 
unclear but studies on p53null CSCs advanced a hypothesis on the role of p53 in CSC 
mitotic division (Gatza et al., 2008). 
 
CSCs and p53 
According to the first studies on the role of p53 in SC division, it has been reported 
that p53 imposes an asymmetric proliferative fate on daughter cells both in mouse 
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embryo fibroblasts and in one mammary epithelial cell line (Rambhatla et al., 2001) 
while the loss of p53 was found to increase self-renewal of neural SC in a sphere-
forming assay arguing a switch from an asymmetric to a symmetric phenotype 
(Meletis et al., 2006; Piltti et al., 2006). In support of this, p53 null CSCs are near 
immortal in culture due to not ended self-renewal and undergo symmetric self-
renewing divisions; in the p53null mammary gland, CSC number is increased and they 
expand progressively, thus indicating that p53null SCs divide symmetrically also in 
vivo. On the other hand an increased WT p53 activity (p53+/m mice) has decreased 
regenerative capabilities upon serial transplantation, suggesting early stem cell 
exhaustion (Gatza et al., 2008).  
 
p53 loss in CSCs: symmetric trend of division 
The loss of p53 in levels and activity, because of its overt reported role of “guardian 
of genome” (Lane et al., 1992), has plausibly consequences on SC proper 
mechanisms as the asymmetric division.   
Cicalese recently reported evidences of p53 involvement in the positive regulation of 
asymmetric vs. symmetric division in CSC murine model (Cicalese et al., 2009) 
proofing how the frequency of symmetric self-renewing divisions in CSCs is 
increased due to attenuated p53-signaling. Colaluca furthermore showed that the 
cell fate determinant Numb mediates the increase in p53 levels and activity, and the 
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regulation of p53-dependent phenotypes, through the formation of a Numb-p53-
HDM2 ternary complex (Colaluca et al., 2008). These observations imply that p53, 
together with other tumor suppressors like Numb, could play a pivotal role in the 
regulation of SC self-renewal in the mammary gland by imposing an asymmetric 
mode thus self-renewing divisions.  
 
p53 loss in CSCs: a possible solution 
All together the previous finding suggest the possibility that p53 carries out its tumor 
suppression function by regulating self-renewal division. The deregulation of the 
machinery that controls and ensures the correct balance between symmetric and 
asymmetric SC division may lead to alteration of tissue homeostasis, increase of the 
SC pool and, finally, cancer.  
According to that, since p53 is a potent suppressor of mammary transformation, an 
inhibition of SC symmetric divisions by p53 restoration could lead to tumor 
suppression in the mammary epithelium. The direct answer to this hypothesis comes 
from in vitro pharmacological approach where Nutlin, rescuing p53 activity, leads to 
rapid exhaustion of cultured mammospheres converting the prevailing mode of 
division of ErbB2 tumor SCs from symmetric to asymmetric and reduces tumor 
growth (Cicalese et al., 2009). 
 
	   39	  
p53 targeted therapy: Nutlin 
Because of its involvement in p53 homeostasis and in SC fate determination, MDM2 
could be a target for cancer therapeutic intervention (Freeman et al., 2000). Indeed 
once freed from MDM2, p53 rapidly accumulates in the nuclei of cancer cells, 
activates p53 target genes and the p53 pathway, resulting in cell-cycle arrest and 
apoptosis. 
MDM2 can down-regulate p53 only if the p53-MDM2 complex takes place. 
Therefore, inhibition of MDM2–p53 binding is a possible strategy for p53 
stabilization and activation (Vassilev et al., 2007). 
This result can be obtained by the use of a small molecule inhibitor, for example 
Nutlin, a cis-imidazoline compound (Tovar et al., 2006). 
As other MDM2 inhibitors, Nutlin can block the p53-MDM2 complex formation. 
Crystal-structure studies demonstrated that Nutlin binds to a MDM2 hydrophobic 
cleft provided with crucial amino acid residues for p53-MDM2 coupling. Nutlin 
remarkably mimics their molecular interactions and by binding MDM2, it can dismiss 
p53 from this interaction, in that way, Nutlin preserves p53 levels and activity 
bringing to cell cycle arrest and suppresses tumor growth in vivo (Vassilev et al., 
2004) (Bottger et al., 1997b; Blaydes et al., 1997 Brown et al., 2009). 
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The “cancer stem cell-targeting therapy” 
The major issue in cancer therapy is the explanation of tumor relapse after 
chemotherapy or irradiation treatment. Current therapies, in fact, have been 
developed to target the bulk of the tumor mass, so far the only approach successful 
to reduce tumors. Unfortunately, it seems that both normal and CSCs are more 
resistant to chemotherapy than their differentiated progenies. This fact may be due 
to an increased expression of anti-apoptotic proteins, such as those of the BCL-2 
family (Al-Hajj et al., 2003; Reya et al., 2001), or of transporting proteins, such as 
MDR1 and ABC transporters (Jordan et al., 2006). Due to their ability to remain 
quiescent, SCs are relatively resistant to cytostatic drugs, which act mainly on 
dividing cells (Gil et al., 2008; Reya et al., 2001; Visvader and Lindeman, 2008), 
therefore, despite dramatic responses on the tumor mass, these therapies could 
affect only the differentiated progenies of CSCs since the rare CSCs are not targeted. 
In contrast, CSC-targeted therapies that foresee the selective ablation of the rare 
CSCs, may represent an attractive method to eradicate the whole tumor mass (Fig. 4). 
Despite several studies supporting this strategy, (Guzman et al., 2005; Yilmaz et al., 
2006; Piccirillo et al., 2006) there is only little experimental evidence that the 
selective ablation of CSCs would lead to the killing of the entire tumor mass without 
affecting normal SCs and their differentiated offspring (Jordan et al., 2006; Tan et al., 
2006; Visvader and Lindeman, 2008). 
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Figure 4 
Cancer SC-targeted therapy 
Conventional therapies may shrink tumors by killing mainly differentiated SC progenies. 
Cancer SCs, less sensitive to these therapies, could remain viable and re-establish the 
tumor. By contrast, therapies specifically targeting cancer SCs could arrest tumor 
maintenance or growth. 
Modified from Reya et al., 2001. 
 
In this thesis I report my investigations on the characterization of the biological and 
molecular features of Numb KO murine breast model in comparison with Numb 
deficient human breast cells model. I exploited an in vitro system (the mammosphere 
assay) to propagate and enrich breast SCs, in combination with a cell membrane 
labeling system (PKH-assay) to purify SCs. 
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The absence of Numb in both murine and human models helped to clarify the role of 
this “fate determinant” starting from the SC first mitotic division in vitro up to the in 
vivo tumorigenesis and related Numb reconstitution consequences. 
Through the comparison of the self-renewal properties of normal and cancer SCs, 
both in terms of proliferative cell fate and Numb partitioning, and the study of the 
molecular mechanisms underlying abnormal growth properties, functional 
attenuation and pharmacological restoration of signaling pathways in mammary 
CSCs, I have attempted answer the open questions regarding the role of SCs in cancer 
development and maintenance, focusing the attention on a first possible direct 
evidence for cancer SC targeted therapy.  
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Numb is asymmetrically distributed at SC mitosis and 
partitions into the “stem” daughter cell. 
According to the first studies carried on Drosophila, focused on Numb partition 
dynamics during stem cells (SCs) mitosis, Numb acquires a polarized distribution, it 
concentrates in the plasma membrane area overlying only one of the two spindle 
poles, than segregates into one of the two daughter cells (Rhyu et al., 1994). This 
asymmetrical distribution in Drosophila triggered the interest on Numb and enhanced 
the study of several scientific groups.   
Recently our scientific group demonstrated that during mouse and human mammary 
SCs (MSCs) cytokinesis, Numb is partitioned unequally, segregating into one of the 
two daughter cells (Cicalese et al., 2009; Pece et al., 2010). In the current work, we 
exploited the PKH26 dye-based methodology (Cicalese et al., 2009; Pece et al., 2010) 
to verify whether Numb segregates into the daughter cell that retains the SC identity 
(the “stem” daughter cell) or into the one that assumes a progenitor fate (the 
“progenitor”).  
Five weeks old mice mammary glands were surgically explanted, reduced 
mechanically and digested as described in Materials and Methods (Tissue collection 
and digestion). Epithelial cells were purified from the bulk mammary cell population, 
seeded in SC selective medium (MESCM) and let grow in non-adherent condition. SCs 
are relatively quiescent and survive in anchorage independent conditions 
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withstanding anoikis, an apoptotic process due to anchorage detachment. In these 
conditions a single SC proliferates in suspension as a floating spherical clonal 
structure since the innate shape reachable in non-adherent condition by dividing 
cells is the sphere; this culture method selects for the SC growth and for the 
formation of the so called mammosphere (MS). 
A single WT MS is structured by ~300 progenitor cells and contains only one SC, 
(Cicalese et al., 2009), thereby SCs compose a small fraction of the entire dissociated 
bulk mammary epithelial cell population. SCs were purified from this first generation 
of MSs throughout the use of PKH26 (see Materials and Methods “Isolation of primary 
SCs from mouse breast”). PKH26 is a lipophilic dye and it was used to stain the bulk 
mammary population before undergoing the selective culture method. PKH26 stains 
all the cells, SCs included. This dye will be half-retained by the SC from the first 
mitotic division, while progressively diluted by the counterpart of progenitors cells 
(PC) undergoing several following rounds of mitosis until reaching the number liable 
for MS size. 
To track the SCs, aware of their quiescent or slowly dividing state, the employment of 
a lentiviral infection was chosen. A single cell population from dissociated MSs was 
stained with PKH-488, the green fluorescent analog of red PKH26, and lentivirally 
transduced with Numb-DsRed; the first rounds of mitotic division were monitored by 
time-lapse (TL) video-microscopy. Exploiting PKH-488 we were able to identify the 
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SC as the cell retaining the higher amount of lipophilic dye after the very first mitotic 
division and during the following ones; in the mean while the DsRed signal carried by 
Numb allowed us to track Numb distribution. Our aim was to see whether Numb was 
equally divided between the two daughter cells or rather retained by one of them. 
The TL identified the PKHpos SC as the Numb-retaining cell (Fig. 1). Together with the 
identification of the Numb retaining daughter cell, TL analysis helper us to study the 
SC first mitotic division discriminating between symmetric and asymmetric mode. 
The mode of SC division was established by two criteria  
• an initial asymmetric division of the SC, followed by symmetric divisions of the 
progenitor, led to a typical 1-2-3-5 progression in the cell number; conversely a 
symmetric division of the SC led to a 1-2-4 pattern;  
• retrospectively the “stem” daughter cell was identified as the cell that remained 
quiescent and therefore retained the PKH-488 dye (Cicalese et al., 2009; Pece et al., 
2010), while the progenitor divided further to yield a limited progeny; this pattern 
was clearly identifiable only when an initial asymmetric division had occurred, since a 
fully symmetric pattern of SC division led to progressive dilution of the dye.  
We found that, predominantly, MSCs divided asymmetrically and that Numb 
partitioned in the cell retaining the PKH dye, thereby the “stem” daughter cell (Fig. 2).  
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Figure 1 
Time Lapse analysis. Numb partition in SC first mitotic division 
Mouse MECs were labeled with PKH 448 and pLVX puro Numb DsRed. Quiescent/slowly 
dividing SCs fraction retained PKH dye during the first divisions (green). 488 nm green 
light tracks SCs (yellow arrows) in the forming MS. 660 nm red light: Numb DsRed Merge 
panel is presented both in fluorescence and bright field (b.f+merge)    
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Figure 2 
TL statistical analysis.  
Numb partition in first mitotic division. Cake graph on the left summarizes the percentage 
of asymmetric vs. symmetric events on total number of 56 observations. 
The graph on the right estimates the percentage of co-segregations Numb/PKHhigh pos cells 
on total 32 mitotic divisions observed. 
 
Numb KO and Numb KD: loss of Numb causes replicative symmetry in MSCs 
Once identified the Numb-retaining daughter cell as stem cell, we investigated the 
consequences of Numb ablation in MSCs. To perform this study we exploited both 
the in vitro and the in vivo approach.  
The in vivo implications of Numb loss were studied throughout the Numb KO 
engineered mouse model that was obtained using the CRE-loxP recombinase system 
(Wang Y et al., 1996).  
Within the normal mammary gland, the SCs are located within the epithelial basal 
compartment. These cells express both luminal (citokeratin CK8, CK18) and 
	   49	  
basal/myo-epithelial markers (cytokeratin CK5, CK6, CK14) (Howard et al., 2000; 
Petersen et al., 2010)  
The use of the CK5 promoter let us to specifically knock down Numb in the stem cell 
compartment. CK5 transcription is regulated by its CK5 promoter that is active in 
breast and in several epithelial tissues, including the basal cell layer of the epidermis, 
hair follicles, oral epithelium, vagina, stomach, esophagus, bladder, and thymus 
(Ramirez et al., 1994; Stingl et al., 2006; Pece et al., 2010). To obtain the Numb KO 
mouse model we crossed Cre-loxP conditional Numb-KO mice (Zilian et al., 2001 
Wilson et al., 2007) with CK5-Cre mice (Ramirez et al., 2004) (see Materials and 
Methods “The Cre/loxP recombination system in transgenic mice”). 
 
Aim of the work 
The aim of the project is to study the role of Numb and the consequences of its loss 
in breast stem compartment. To reach this goal we developed the murine Numb KO 
model exploiting the Cre/loxP recombination system. The Numb KO mouse lacks in 
Numb in all the tissues in which K5 is active and among these, the breast is included. 
In support to this strategy and to validate the results coming from Numb KO mouse 
model we could count on Numb KD in vitro model using ShRNA (short hairpin) 
silencing technique in WT murine breast primary cells. 
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Numb Knocking Out: efficacy of murine model 
To verify whether Numb KO murine model displayed correctly Numb loss in breast 
and in stem cell compartment, biochemical analysis (Western Blot) was carried on the 
primary mammary epithelial cells (MECs) obtained from breast digestion of Numb KO 
mice breast and related spawned MSs. 
Numb KO mice breast confirm a markedly reduced Numb level both in MECs and MSs, 
thereby we step forward analyzing first of all the possible in vivo phonotypical effects 
of Numb loss and than, through in vitro assays, we tested Numb KO MECs sphere 
forming efficiency (SFE) and related MS propagation.  
 
Numb KO in vivo read out 
Numb KO mice breast did not display evident morphological changes to a first 
necroscopical analysis. We thereby decided to perform a whole mount analysis on the 
entire fat pad. This approach consist in a low magnification screening to get 
information about possible gross alterations of the major structures composing the 
breast fat pad. This histological technique permits to focus the attention on number 
and dimension of primary and secondary ducts, rate of branching and acini size. 
Whole mount analysis was performed using Carmine Alum technique (see Materials 
and Methods “Mammary gland Whole Mount staining with Carmine Alum”), and it was 
accompanied by classical histological investigation with hematoxilin/eosin (H/e) 
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staining for a higher magnification analysis that put in evidence enlarged and 
hyperbranched ducts (Fig. 3c,d; Fig. 4b) together with hyperplastic (Fig. 4c; Fig. 5b, 
c), dysplastic and preneoplastic lesions, such as hyperplastic alveolar nodules (HANs) 
(Medina et al., 1976, 1996; Cardiff, et al., 2000). 
This is the most extensively characterized lesion and it is similar to the differentiated 
alveolar cells normally found in pregnant mammary gland of lactating mice. HANs 
were originally identified as persistent focal areas of alveolar hyperplasia in non-
pregnant mice. 
These morphological evidences strongly argue a fundamental role of Numb in breast 
tumorigenesis, emerging from the analysis of phenotype obtained throughout its loss 
in murine Numb KO model. 
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Figure 3 
Numb KO mouse model: macroscopic breast analysis. 
Carmine Alum staining was used on whole mount inguinal breasts to investigate the ductal 
architecture. 
(a) WT control breast phenotype, magnification in figure b. 
(c) Numb KO2 breast phenotype, magnification in figure d. 
	   53	  
 
Figure 4 
H/e microscopic breast analysis on FFPE: Comparison between WT and Numb KO mouse 
breast: 
(a) Typical bilayered asset of WT epithelial duct with correctly sized lumen. 
(b) Possible Numb KO phenotype: enlarged duct with filled lumen delimitated by stretched 
epithelium. 
(c) Possible Numb KO phenotype: Hyperplastic Duct, loss of epithelial architecture, 
reduced/absent lumen 
(d) Ductal hyperbranching (black arrow): Numb KO breast displays increased number of 
secondary ducts exiting from primary ducts side.  
 
Figure 5 
Numb KO mouse model: microscopic breast analysis. 
H/e analysis of FFPE Numb KO2 breast. In evidence the presence of both normal and 
hyperplastic ducts in the same sample (black arrows). Representative images are shown.  
 
Numb KO in vitro read out 
Biochemical analysis (Western Blot - WB) carried on that primary mammary epithelial 
cells (MECs) obtained from breast digestion of Numb KO mice breast displayed 
markedly reduced Numb levels (Fig. 6a,b). According to previous studies (Colaluca et 
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al., 2008; Pece et al., 2004), Numb plays a crucial role in two major pathways. Numb 
has been demonstrated to inhibit Notch function preventing its translocation to the 
nucleus inducing its ubiquitination and meanwhile controlling Notch intracellular 
domain degradation (McGill & McGlade 2003; Pece et al., 2004). Recently Numb has 
been entrusted with the role of p53 regulator, participating in the formation of the 
Numb-p53-MDM2 tricomplex, which is responsible for the regulation on p53 
ubiquitinilation and than the control of p53 homeostasis (Colaluca et al., 2008). 
Therefore a possible approach was identified in the biochemical analysis of the 
molecular partners interacting with p53 and Notch in order to verify whether the loss 
of Numb brought to changes in their activity. QPCR analysis reports how the loss of 
Numb causes decreased p53 levels respect to WT counterpart and congruent 
alterations of positively regulated (mdm2, p21) and negatively-regulated (nanog) p53 
targets (Fig. 6c). Furthermore Notch activity is enhanced, proofed by increased 
transcription of the Notch targets, hey1 and hey2 (Fig. 6c). A similar alteration at the 
level of p53 and Notch pathways has been seen in the Numb KD MSs (Fig. 6c). 
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Figure 6 
Analysis of the efficiency of conditional Numb Knocking Out in mouse MECs and related 
spawned MSs.  
(a, b) Immunoblot analysis of Numb expression in total cell lysates (30µg) of MEC and 
related spawned MSs Both Numb KO1 and KO2 lines were considered in MMECs analysis. 
Numb levels were detected with Ab#21 monoclonal antibody. Vinculin was detected as a 
protein loading control.  
(c) QPCR analysis of Numb targeted factors mRNA relative expression. Hey1, hey2 and 
nanog levels were considered as readout of Notch signaling, p21 and MDM2 levels for p53 
activity. Immunoblots are representative of 2 experimental repeats. 
Numb KO cells in vitro propagation: the Mammosphere assay  
Since p53 is largely considered one of the major tumor suppressors controlling cell 
cycle and cell homeostasis (Lane et al., 1992), often involved in different tissues 
tumorigeneris. The Cancer Stem Cells (CSCs) theory (Clarke et al., 2006) identifies in 
CSCs expansion the responsible for tumorigeneris as well as for tumor relapse; 
following this hypothesis, we decided to investigate on a possible SC compartment 
expansion in Numb KO model, where, as previously said, the loss of Numb brings to 
a decreased p53 activity.  
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To verify whether the loss of Numb levels and activity by knocking out had caused an 
expansion of the SC compartment we performed the in vitro Mammosphere assay 
(see Material and Methods: Mammosphere assay and SFE). This experiment consists 
in a precise retroactive study of SCs number relying on the sphere number found 
after a determined period of MECs culture. The combination of SCs culture medium 
(MESCM see Material and Methods) and the lack of adhesion, let only the SCs 
proliferate spawning floating spheroid colonies, identified as mammospheres (MSs) 
and their final number is indicative of the SCs number included in the early bulk 
population. The final number of spheres divided for the starting number of cell 
seeded (multiplied for 100) scores the Sphere Forming Efficiency index. 
Thereby the sphere size can be easily calculated by disaggregating the MSs to a 
single cell suspension; the number of cells obtained divided for starting MSs number 
gives a value to MSs size.  
This assay allows us to estimate the starting number of SCs in a sample, their self-
renewing potential and nevertheless to notice a possible SC number increase upon 
serial propagation in vitro. This last step consists in a prolonged culture assay 
throughout consecutive passages. MSs were mechanically desaggregated and seeded 
in single cell suspension to let the next generation MSs grow. Indeed once the SC is 
released from its PCs envelope that inhibited SCs mitosis, the SC can divide again 
spawning another sphere; that process can be repeated up to 3/4 times in WT sample 
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until the self-renewing extinguishment. On the other hand, in tumor samples, as 
previously demonstrated (Cicalese et al., 2009; Pece et al., 2010), CSCs grow in 
number throughout the generations in vitro bringing to an increase in SFE index and 
MSs size. In that case the self-renewing potential is unlimited and the sphere 
propagation can be carried on for a not ended number of generations.  
To quantify the starting SC number in out samples we exploited the Fluorescence-
activated cell sorting (FACS) analysis. Bulk MEC population obtained from digestion of 
WT and Numb KO breasts were counted, stained with PKH26 and seeded in 5/6 days 
selective SC culture (absence of adhesion in MESCM). PKH26 is a lipophilic dye that is 
half-retained by the SC thereby resulting PKHHIGH stained from the first mitotic 
division, while progressively diluted by the counterpart of progenitors cells (PC) 
undergoing several following rounds of mitosis (thereby PKHLOW and PKH NEG). FACS 
discriminates and collects PKHHIGH SCs hence purified from the mammary epithelial 
buck population (see Materials and Methods “Isolation of primary SCs from mouse 
breast”). 
We tested both MECs and derived MSs, obtained from individual Numb-KO mice and 
WT mice. Numb-KO MECs contained ~3-4-fold more SCs than WT ones, with a SC 
frequency of ~1:8,000 in Numb-KO, and ~1:30,000 in WT cells (Tosoni Unpublished 
preliminary data).  
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Throughout in vitro analysis we observed that the 1st generation WT MSs were 
approximately ~100µm sized and contained ~300 cells/MS, with a SFE of ~0.3%, in 
agreement with the assumption of the correlation between the number of SCs and 
spawned MSs proposed in previous reports (Cicalese et al., 2009). On the other hand, 
MSs originated from Numb-KO MECs were ~2-fold larger (~500-600 cells/MS) and 
showed a ~2-3-fold higher SFE.  
The bigger size of these MSs and the higher SFE index of their constituting cells 
argue a higher amount of SCs inside them: we estimated a frequency of ~4-5 SCs per 
MS. We observed moreover that MSs derived in vitro from Numb-KO MECs had a SCs 
frequency of ~1:150/200 (Tosoni Unpublished preliminary data). 
Upon serial propagation in vitro, WT-MSs progressively lost self-renewal ability, 
consistent with previous reports in mouse and human (Cicalese et al., 2009; Pece et 
al., 2010). Conversely, the number of Numb-KO MS increased over time, with a 
constant ~2-3-fold expansion rate. In agreement with the correspondence between 
the starting SC number and the spawned MS (Cicalese et al., 2009; Pece et al., 2010), 
the observed increase of MS number through the consecutive passages in vitro 
argues a SC compartment expansion in Numb KO model. The step responsible of this 
event is the SC first mitosis, when the SC should divide in 1 SC and 1 progenitor 
following an asymmetric mode (see “Mode of division in SCs”). If a symmetric division 
occurs, the SC divides in 2 SC amplifying the resulting SC pool. 
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Throughout the time-lapse (TL) video-microscopy approach, we were able to 
demonstrate how Numb-KO SCs divided predominantly in a symmetric fashion (90%, 
Fig. 12b), and with a faster division rate compared to WT cells. The entire set of 
observations was replicated using an alternative strategy, the functional ablation (in 
vitro Numb KD) of Numb in WT-MECs (Fig. 7, Fig. 8).  
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Numb Knocking Down in vitro 
Similar results were obtained from in vitro Numb KD. WT MECs were infected with the 
lentiviral construct pLKO Sh Numb exploiting the ShRNA (short hairpin) silencing 
technique (see Materials and Methods). Among several constructs, pLKO #39 was 
chosen for its efficacy witnessed by biochemical analysis (WB Fig. 7a). Therefore a 
possible approach was identified in the biochemical analysis of the molecular 
partners interacting with p53 and Notch in order to verify whether the loss of Numb 
brought to changes in their activity. WB analysis and QPCR report how the loss of 
Numb causes decreased p53 levels (Fig. 7b) respect to WT counterpart and congruent 
alterations of positively regulated (mdm2, p21) (Fig. 7b,c) and negatively-regulated 
(nanog) p53 targets (Fig. 7c). 
Furthermore Notch activity is enhanced, proofed by increased transcription of the 
Notch targets, hey1 and hey2 (Fig. 7c). A similar alteration at the level of p53 and 
Notch pathways has been seen in the Numb KD MSs.  
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Figure 7 
Analysis of the efficiency of ShRNA technique Numb Knocking Down in mouse WT MECs and 
related spawned MSs.  
(a) Immunoblot analysis of Numb expression in total cell lysates (30µg) of MMECs after 
infection with PLKO Sh35,36,38,39. PLKO Sh39 was chosen and PLKO-ShLuc was used as 
negative control.  
(b) Immunoblot analysis of Numb expression in total cell lysates (30µg) of MSs spawn by 
PLKO Sh39 infected MMECs. Both short and long (high exp.) exposure images of Numb and 
p53 immunoblots are reported. Numb levels were detected with Ab#21 monoclonal 
antibody. Vinculin was detected as a protein loading control.  
(c) QPCR analysis of Numb targeted factors mRNA relative expression. Hey1, hey2 and 
nanog levels were considered as readout of Notch signaling, p21 and MDM2 levels for p53 
activity. Immunoblots are representative of 2 experimental repeats. 
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The entire panel of Numb KO in vitro experiment previously exposed was performed 
using Numb KD cells. According to results coming from mammosphere assay, Numb 
KD MSs displayed a bigger size compared to WT (Fig. 8b,d). After having performed 
an in vitro serial propagation we noticed an increasing estimated SFE for these cells 
throughout the consecutive passages, likewise in Numb KO cells (Fig. 8 lower table). 
These data argues a higher amount of SCs inside Numb KD MSs suggesting a 
possible switch from an asymmetric to a symmetric mode of division consequent to 
Numb knocking down. These evidences suggested that Numb silencing is a suitable 
alternative model to reproduce the results obtained from the Numb KO mouse model. 
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Figure 8 
Effects of Numb ablation on SCs organotypic outgrowths in culture suspension and SFE.  
SFE assay was performed on FVB cells collected from first generation sphere mechanical 
desaggregated and repeated for the next 2-4 passages.  
(a) Control cells were infected with PLKO-ShLuc.  
(b) Numb KD was assessed through PLKO Sh39 infection 
(c) Spawned spheres were counted and collected each passage, than desaggregated in 
single cells, of which number was considered to calculate sphere size and next passage SFE 
(d)   
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Aberrant mammary morphogenesis and tumor 
initiation by loss of Numb 
According to previous studies (Hennighausen and Robinson et al., 2001, 2005; 
Smalley and Ashworth, 2003), the SC is the only responsible for tissue 
organogenesis. This means that SCs, when inserted in a permissive context, can 
spawn the entire complex structure of the surrounding environment. In our case, SC 
showed the ability to spawn MSs in vitro as an attempt of morphogenesis. To 
investigate whether SC were able to re-constitute the epithelial tissue structure, we 
transplanted Numb KO bulk MECs and to quantify the SC number, MECs 
transplantation was performed at limiting dilution to score the mammary 
repopulating unit (MRU) index or the cancer initiating cell (CIC) number. These 
indexes are denotive of SC number in the starting bulk MEC population transplanted. 
A range of cell dilution, from 105 to 10 cells was chosen for the injection in 5 weeks 
NOD SCID mice inguinal breast, closed to nipple area where the endogenous 
epithelium is concentrated and the remaining fat pad was cleared to give space to cell 
outgrowth.  
The so obtained outgrowths were analyzed through histological assay in order to 
quantify the epithelial structures. 
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Figure 9 
in vivo Numb KO and Numb KD cell transplantation assay. MRU and CIC frequency. 
(a) Numb KO1 and KO2 MECs lines were transplanted at limiting dilution in cleared fat pad 
mice. A range of cell dilution, from 105 to 10 cells, was chosen and the mammary 
repopulating unit (MRU) index or the cancer initiating cell (CIC) number were calculated on 
the base of the eventual outgrowth obtained. 
(b) MSs spawned by Numb KO1 and KO2 MECs were desaggregated and the obtained cells 
transplanted at the same previous limiting dilution. MRU and CIC frequency were 
calculated. 
(c) Cells obtained from Numb KD MSs desaggregation were transplanted at the same range 
of dilution. MRU and CIC frequency were calculated 
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Macroscopically, the outgrowths generated by WT-MEC and WT-MS cells were 
indistinguishable from the normal mammary gland but after a deeper histological 
analysis, in 7 of 10 cases, the reconstituted mammary tissue generated by Numb-KO 
cells displayed a number of gross morphological alterations. Primarily these 
outgrowths displayed hyper-branched and enlarged ducts alongside areas of ductal 
hyperplasia and severe dysplasia together with preneoplastic lesions such as HANs 
(Medina et al. 1976) and areas of frank malignancy. In a fraction of cases (3 of 10), 
the outgrowths generated by Numb-KO cells were overtly neoplastic; the cells 
obtained from breast digestions of two cases among these were identified as KO1 
and KO2 and chosen to carry on the following experiments in relation to the shown 
tumorigenic skills.  
The selected KO1 and KO2 were transplanted the day after the digestion: cells were 
multiple injected at limiting dilution in order to score their mammary repopulating 
unit (MRU) frequency as readout of their cancer initiating cells (CIC) content.  
Both KO1 and KO2 MECs gave outgrowths with a higher frequency arguing a higher 
SCs fraction if compared to WT MECs; the loss of Numb could be the responsible of 
the SCs (or even CSCs) increase in these Numb KO MECs (Fig. 9a,b). 
The entire set of observations, obtained with Numb-KO MECs, could be replicated 
with the xenotransplantation of MSs spawn by both Numb KO and Numb KD MECs 
(Fig. 9c). 
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The tumorigenic skill of our Numb KO model was even confirmed even by 3D culture 
assay. Indeed, Numb-KO MECs seeded on 3D-organogenic Matrigel assay, generate 
outgrowths displaying features of faulty morphogenesis, with disorganised, filled and 
hyperproliferative structures, as opposed to the typical bilayered and hollowed 
acinar/lobulo-alveolar structures generated by WT-MECs (Fig. 10). 
 
 
 
Figure 10 
3-D Matrigel assay; differences between WT and Numb KO acinis. 
Morphological analysis of overlay seeded WT and Numb KO cells spawned spheres on 
matrigel support 
Left: Bright field and related magnification of WT vs KO MSs. 
Right: Histological (H/e) analysis; confrontation between lumen dimension and epithelial 
structures     
 
	   68	  
As previously demonstrated, Numb unequally partitionates during MSC division 
segregating into the “stem” daughter cell, ruling the asymmetric fate determination 
of the SC itself. 
The subversion of this mechanism, through the loss of Numb expression, switches SC 
division from asymmetric to symmetric, causing the expansion of the SC 
compartment and contributing to the acquisition of a malignant phenotype 
observable in vitro, in MSs expansion (Fig. 8), in vivo, in breast outgrowth (Fig 3,4,5) 
and in matrigel assay organogenesis (Fig. 10).  
 
Numb rescue in vitro and in vivo  
To verify whether Numb restore could revert the malignant phenotype displayed by 
Numb KO MECs and MSs, we infected the Numb KO lines with the pLVX lentiviral 
vector carrying the Numb gene, tagged with DsRed fluorescent protein (Fig 11 right). 
In addition to in vivo Numb tracking, the use of pLVX-Numb-DsRed ensures the 
overexpression of Numb protein; in our context, in Numb KO cells, we tried to rescue 
Numb physiological levels and function. Afterwards we evaluated possible changes in 
MSs size and MECs SFE in vivo upon pLVX-Numb-DsRed infection. 
Reconstituted Numb-KO MECs displayed successful Numb and also p53 rescue in 
terms of protein levels. Moreover, p21 level, which was decreased as consequence of 
p53 fall in Numb KO model, was restored. (WB Fig. 11 left) 
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Figure 11 
Left: Immunoblot. Numb rescued cells upon lentiviral infection 
Right: pLVX-puro lentiviral plasmid carries the fusion protein Numb-DsRed.  
Numb was re-expressed in Numb KO cells.  
pLVX EV infection (-), pLVX puro NumbDsRed infection (+). 
Total cell lysates (30µg) from Numb KO (-) and Numb re-expressed Numb KO (+) were 
immunoblotted with Ab#21 monoclonal antibody. Anti p53 (Cell Signaling) Anti p21 (Santa 
Cruz Biotechnology) were used. GRP94 was detected as a protein loading control. Numb 
levels in Numb re-expressed cells are indicated by red arrow, endogenous Numb levels by 
black arrow. 
 
Effects of Numb rescue can be observed also in Time-Lapse analysis. Numb KO Stem 
Cells perform predominantly symmetric first mitotic divisions; Numb overexpression 
inverts this trend: after infection indeed the majority of observed mitosis showed an 
asymmetric mode of division (Fig. 12b). Evidences of Numb rescue came from in vitro 
analysis of Numb KO MSs grown from pLVX-Numb-DsRed infected MECs. These 
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MECs used to spawn spheres with a ~2-fold decrease SFE if compared with Numb KO 
MECs. These Numb rescued MSs moreover displayed a ~60% smaller size (Fig. 12a). 
 
Figure 12 
in vitro effects of Numb rescue on Numb KO1 cells upon pLVX Numb DsRed lentiviral 
infection. 
(a) Bar graph represents the SFE and MSs size in Numb KO (KO1 -black column) cells and 
the same parameters after Numb recue (KO1+Nb -white column).  
KO1 cells were compared with KO1+Nb cells exploiting TL analysis to get eventual changes 
in 1st mitotic division after Numb rescue. Bar graph “b” reports the ratio between symmetric 
(grey column) and asymmetric (red column) events both in KO1 and KO1+Nb cells.  
Numb re-expressed (pLVX NumbDsRed infected) Numb KO cells were injected in one side 
breast, pLVX-EV infected Numb KO cells were injected as control in the other side breast 
and let both the tumor masses develop. 
in vivo effects are reported in figure “c”. Bar graph displays the differences between the 
tumor volumes reached by Numb KO (KO1) control cells (black column) and Numb rescued 
Numb KO cells (KO1+Nb) (white column). 
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We investigated also the possible effects of Numb rescue in vivo. pLVX-Numb-DsRed 
infected MECs were transplanted in NOD SCID mice. The tumors raised were ~2-fold 
smaller in size compared to mock-infected controls (Fig 12c).  
To exclude the possibility that the smaller size of the tumors was due to increased 
apoptosis or decreased proliferation, we demonstrated by IHC analysis performing an 
anti-KI67 staining that the proliferation was not affected. Moreover Numb 
reconstituted tumors did not show a higher number of Caspase-3 activated cells, 
thereby arguing that these cells do not undergo apoptosis (Fig. 13). 
 
Figure 13 
IHC on tumors derived from Numb KO (KO1) and Numb re-expressed Numb KO (KO1+Nb) 
FFPE sections were stained for KI67 (Thermo Scientific #9106) to score the proliferation 
index. Consecutive sections were stained for Activated Caspase (Cleaved Caspase 3, 
Asp175 Cell Signaling #9661) to quantify the number of apoptotic events. 
Sections were scanned with Aperio ScanScope XT and DAB signal was quantified and 
analyzed with Spectrum Version 11.0.0.72 (Aperio Technologies) 
OCT Frozen sections were DAPI stained and observed in red fluorescent light (560nm). 
Numb DsRed fluorescent fusion protein was detected. 
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According to published data (Cicalese et al. 2009), the tumor suppressor p53 
controls the SC fate ruling the ratio of symmetric vs. asymmetric divisions. According 
to what has been previously shown about the role of Numb in stabilizing p53 protein 
(Colaluca et al 2008), here we show that Numb is required to maintain the correct 
p53 levels in the SC compartment to ensure the proper ration asymmetric vs. 
symmetric divisions. Loss of Numb causes a decrease in p53 levels and activity, and 
the consequence is a switch towards symmetric SC divisions. Thereby, Numb may 
function by modulating p53 activity in the MSC compartment. 
 
p53 rescue: Nutlin-3 in vitro 
Evidences that the Numb-p53 axis might have a role in the control of the MSCs 
number by imposing an asymmetric mode of division came from experiments of 
Numb protein levels rescue and p53 restoration. In particular, Numb control of p53 
homeostasis seems to have a crucial role in tumorigenesis; the issue is that we 
clarified this mechanism by imposing a SC directed approach throughout a lentiviral 
infection, not suitable in clinic strategies.  
Since our aim, as research group committed in experimental oncology, is to carry in 
clinical area our knowhow on molecular dynamics involved in breast tumorigenesis, it 
becomes necessary to develop a pharmacological approach suitable to interfere with 
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the mechanisms responsible for breast tumorigenesis. Thereby we considered as a 
possible direct strategy to hit p53-MDM2 axis.   
The p53–MDM2 autoregulatory feedback loop governs p53 amounts (Wu et al., 
1993). MDM2 is an ubiquitin ligase responsible for p53 ubiquitin-dependent 
proteolytic degradation. Overexpression of MDM2 in human cancer, e.g., gene 
amplification of MDM2, targets p53 and interrupts the p53 network. (see “The p53-
MDM2 axis”). We used Nutlin-3, a cis-imidazoline compound. (Tovar et al. 2006) to 
inhibit p53–MDM2 complex formation. Nutlin-3 as other MDM2 inhibitors, can block 
the p53-MDM2 complex formation. This mechanism is proofed by crystal-structure 
studies demonstrating that Nutlin-3 binds to a MDM2 hydrophobic cleft provided 
with crucial amino acid residues for p53-MDM2 coupling (Kussie et al., 1996). 
Nutlin-3 remarkably mimics p53 in its molecular interactions with its ubiquitin ligase 
MDM2  (Fig. 14 right). By binding MDM2, Nutlin-3 can dismiss p53 preventing its 
ubiquitin-dependent proteolytic degradation. In this way, Nutlin-3 preserves p53 
levels and activity bringing to cell cycle arrest and suppresses tumor growth in vivo 
(Vassilev et al., 2004). The entire set of in vitro Nutlin-3 treatments was performed 
applying 10µM final concentration for 24 and 48 hours. Nutlin-3 treatment was 
performed both in cell suspension for biochemical analysis and in Methylcellulose-
based medium (MethoCult™ Stemcell Technologies) for TL experiments. Since Nutlin-
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3 powder was resuspended in DMSO (according to product datasheet) all the control 
samples were treated with an equal volume of DMSO. 
Given that Numb-KO MSCs had overall lower p53 level and activity because of the 
lack of Numb, as previously demonstrated by Numb in vitro rescue in Numb KO cells 
upon pLVX-Numb-DsRed infection, we treated Numb KO cells from dissociated MSs 
to Nutlin-3 to test whether the restoration of p53 activity could restore the 
asymmetric mode of division and prevent the expansion of the SC compartment. 
Biochemical analysis (WB) confirmed p53 levels restoration after Nutlin-3 treatment; 
even p53 activity is restored as shown by p21 level, susceptible to p53 positive 
regulation (Fig.14 left). 
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Figure 14 
Left: Immunoblot. p53 rescue via Nutlin-3 in vitro treatment. 
Numb KO (KO1) cells were treated with 10 µM Nutlin-3 for 24h Total cell lysates (30µg) 
from DMSO treated KO1 (-) as control and Nutlin-3 treated KO1 (+) were immunoblotted 
with Anti p53 (Cell Signaling) Anti p21 (Santa Cruz Biotechnology). GRP94 was detected as 
a protein loading control. 
Right: Nutlin-3 fills MDM2 pocket avoiding MDM2-p53 binding.  
Figure adapted from Nalepa et al, 2006  
 
The mammosphere assay performed on Nutlin-3 treated Numb KO cells put in 
evidence a drug dependent SFE reduction accompanied by a significant decrease in 
MS average size (Fig. 15a), whereas, consistent with previous reports (Cicalese et al., 
2009), no effect was observed on the growth of control MSs.  
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Figure 15 
in vitro effects of p53 rescue via 10 µM Nutlin-3 treatment on Numb KO cells  
(a) Bar graph represents the SFE and MS size in DMSO treated (control) Numb KO cells (KO1 
-black column); the same parameters where considered after 24 hours 10 µM Nutlin-3 
treatment (Nutl 10 µM -white column) and p53 rescue validation (Western Blot Fig. 13 left). 
Control KO1 cells were compared with Nutlin-3 treated KO1 cells exploiting TL analysis to 
get eventual changes in 1st mitotic division after p53 rescue. Bar graph “b” reports the 
ratio between symmetric (grey column) and asymmetric (red column) events both in control 
KO1 and Nutlin-3 treated KO1 cells.  
 
TL analysis was performed to verify whether Nutlin-3 treatment also had skewed the 
mode of first mitotic division. Numb KO cells use to divide in symmetric mode in 
almost the totality of mitosis observed. That involves an increase in SC compartment 
since the first mitosis produces two SC, doubling their number throughout the serial 
propagation in vitro. Nutlin-3 treatment induced Numb KO cells to switch their mode 
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of division, from a complete symmetric fashion to an almost equal distribution of 
symmetric and asymmetric events (Fig. 15b).  
This last data in particular focus the attention on a possible Nutlin-3 dependent 
reduction in SC compartment that would lead to decrease in Numb KO cells 
tumorigenic potential. This hypothesis pushed us to perform the next set of in vivo 
experiments.   
 
Loss of Numb-induced tumorigenesis is p53-dependent 
According to the results obtained by mammosphere assay performed on Numb KO 
cells undergone to Nutlin-3 in vitro treatment, likewise SFE and MSs size reduction 
and nevertheless evident switch in SCs first mitotic division mode, we reasoned that 
deregulation of p53 function, as a consequence of the absence of Numb, might be 
the mechanism responsible for the tumorigenic properties of Numb-KO model and 
these properties may be related to Numb KO SC content.  
In fact we previously verified that the tumorigenicity of these cells was Numb-
dependent; by restoring Numb expression (pLVX Numb-DsRed infection) we obtained 
an increase of p53 levels and function accompanied by SFE reduction and sizeable 
switch from symmetric to asymmetric division. Given that Numb KO cells displayed 
sensibility to Nutlin-3 in vitro treatment, proofed even in these context by increased 
p53 levels and function, SFE reduction increase in asymmetric division events, we 
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considered the possibility that tumors grown from Nutlin-3 in vitro treated cells 
should be sensitive to Nutlin-3 mediated p53 restoration  
To test this hypothesis, we selected a Numb-KO MEC primary line that grew as 
tumors (identified as KO1) in the mammary fat pad transplantation assay. Numb KO 
MECs were Nutlin-3 in vitro treated in order to revert the tumorigenic phenotype of 
KO1 line, and than transplanted in NOD SCID mice.  
Nutlin-3 treatment resulted in tumors that were half the size of control tumors (Fig. 
15-2). 
 
 
Figure 15-2 
in vivo effects of in vitro Nutlin-3 treatment on KO1 cells  
in vitro Nutlin-3 treated KO1 cells were injected in one side breast, DMSO treated KO1 cells 
were injected as control in the other side breast and let both the tumor masses develop. 
Bar graph displays the differences between the tumor volumes reached by KO1 control cells 
(black column) and Nutlin-3 treated KO1 cells (white column). 
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To study the effects of Nutlin-3 in vivo treatment on Numb KO MECs, we 
transplanted untreated KO1 cells and allowed tumors to reach a palpable size of ~0.5 
cm in diameter prior Nutlin-3 in vivo treatment (Fig.16a dashed red line). 
Nutlin3 was administered intraperitoneally every 3 days for 12 days (4 treatments) 
using a dose of 20 mg/kg). At the end of the treatment, tumors in Nutlin3-treated 
mice had continued to expand at the same rate as tumors in mock-treated mice 
(Fig.16a) reaching the same size. This result identifies the SC compartment as Nutlin-
3 specific target. Indeed by injecting the drug in the palpable tumor lesion, no 
evident changes in tumor volume can be seen because the tumor size growth is 
dependent on progenitors proliferation. Once the first mitotic division has taken 
place and the first progenitor cell spawn, the SC can even be treated with Nutlin-3 
and new SC divisions prevented, but the progenitor, that is not sensitive to Nutlin-3, 
will undergo to successive mitosis and lead the tumor growth.  
To verify this hypothesis, we performed mammosphere assay on MECs obtained from 
tumors derived from in vivo Nutlin3-treated animals, these samples displayed a 
decreased SFE, if compared to mock-treated animals (Fig.16c). A significant 
difference became apparent even upon re-transplantation, indeed the second 
generation tumors that were obtained from MECs derived from Nutlin-3 in vivo 
treated mice displayed decreased growth rate, indeed they were ~2-fold smaller 
respect to tumors from mock-treated animals (Fig. 16b). 
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The Numb KO – Nutlin-3 treated tumors generated in the following transplantation 
assay were smaller compared to control counterpart as a consequence of the in vivo 
Nutlin-3 treatment, which reduced the number of SCs. 
 
Figure 16 
Effects of p53 rescue via 10 µM Nutlin-3 in vivo treatment on Numb KO tumors. 
Numb KO (KO1) cells were injected in both breast and let the tumor mass develop. 
(a) Nutlin3 (20 mg/kg) was administered intraperitoneally when the lesion was ~0.5 cm in 
diameter (dashed red line). The bar graph shows the difference between the tumor size 
reached by DMSO treated KO1 tumor (Ctrl –black column) and the Nutlin-3 treated KO1 
tumor (Nutl. 10 µM –white column). 
(b) MECs obtained from previous tumors were re-transplanted. The bar graph displays the 
difference between the second generation tumor sizes reached. 
Ctrl (black column) identifies the tumor originated from MECs belonging to DMSO treated 
KO1. 
The white column (Nutl. 10 µM) represents the tumor originated from MECs belonging to 
Nutlin-3 in vivo treated KO1 tumor. 
(c) The second generation tumors were digested and SFE assay was performed on MECs 
obtained. 
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This result confirms the evidence of Nutlin-3 direct action on SCs before the first 
mitotic division, since only the second generation tumor size displays the effects of 
Nutlin-3, which by hitting directly the SCs can limit the progenitor outcome and 
minimizing the overall tumor growth. 
To demonstrate that the difference in tumor size was not related to tumor cell 
proliferation rather than any increase in apoptotic rate we performed IHC 
investigating on KI67 and activated Caspase-3 levels. 
IHC analysis confirms that Nutlin-3 had minimal effects on the bulk tumor cell 
proliferation or apoptosis. Staining for KI67 and activated Caspase-3 does not reveal 
any substantial difference independently of whether Numb-KO tumors were 
generated by cells pre-treated in vitro prior to transplantation (Fig. 17 left) or by re-
implantation of cells isolated from Numb-KO tumors treated in vivo (Fig. 17 right). 
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Figure 17 
IHC on tumors derived from not treated Numb KO (Ctrl) and in vivo Nutlin-3 treated Numb 
KO (Nutlin). Comparison between Nutlin-3 in vitro treatment prior to transplantation (left) 
and re-implantation of cells isolated from Nutlin-3 in vivo treated Numb-KO tumors 
(right).  
FFPE sections were stained for KI67 (Thermo Scientific #9106) to score the proliferation 
index. 
Consecutive sections were stained for Activated Caspase (Cleaved Caspase 3, Asp175 Cell 
Signaling #9661) to quantify the number of apoptotic events. 
 
The above results show how the loss of Numb, controlling the p53 levels and the 
numbers of SCs, contributes to tumorigenesis. 
By the way p53 pharmacological rescue by Nutlin-3 displayed efficacy on SCs 
compartment in case of prior in vitro SCs treatment and furthermore on second 
generation tumor transplants (which were not further exposed to the drug). 
The fact that Nutlin-3 was ineffective on first generation tumors, while being 
efficacious on second generation ones, would predict this drug for a SC-specific 
therapy aimed to tumor relapse treatment. 
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From mouse to human 
Our results put in evidence the importance of Numb in regulating mouse SC 
homeostasis and the effects in terms of tumorigenesis that Numb loss brings to. 
According to that, we wanted to verify whether the Numb-p53 circuitry was 
important also for the human MSC model system. 
IEO Hospital in agreement with the Molecular Medicine program guaranteed us the 
possibility to access to human tumor biopsies. Under strict supervision by Anatomo-
Pathology Unit, and only in case of permission by patients undergoing tumor surgical 
removal, we were allowed to collect human tumor samples in close period to surgery 
and to perform both in vitro and in vivo experiments throughout xenograft in mouse 
model. 
According to published data (Westhoff et al., 2009) one third of all breast tumors 
display the loss of Numb protein, an event that correlates with aggressive disease 
and poor prognosis. Moreover Pece et al focused their study on the correlation 
between Numb expression and tumor prognosis. According to The Gleason system 
(Gleason & Mellinger 2002) which classifies tumors on the base of their level of 
differentiation and grade of complexity, scoring from a G1 to a G3 class where a G1 
represents a well differentiated type of tumor while a G3 is a poorly differentiated 
kind, Pece et al demonstrated that G3 (but also G1 tumors) resulted enriched in 
cancer-initiating cells. The high grade of complexity and aggressiveness of a G3 
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tumor could be so linked to its content in MSCs. (Pece et al., 2010). The high-grade 
tumors were searched, collected and reduced to MECs throughout enzymatic 
digestion.  
We looked for tumors that, independently of their Numb status, displayed 
comparable exponential MSs growth and SFE (Fig. 18). Among these we finally 
selected MECs from two Numb-deficient (Numb-) and two Numb-proficient (Numb+) 
tumors that were carried for control analysis. 
 
 
Figure 18 
SFE assay on human tumor samples 
Numb deficient (T1 and T2, Numb-) and Numb proficient (T3 and T4, Numb+) selected 
samples were tested to score in vitro MECs SFE on the base of the cumulative sphere 
number through at least 4 MS generations. 
 
Validation of human xenografted Numb deficient model 
To reproduce in NOD SCID mouse model the context displayed by human tumors and 
to perform in vivo experiments on these samples, we xenografted human MECs 
derived from the related tumor digestion in in NOD SCID mice. In order to verity 
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whether Numb levels of expression was retained even after xenograft, we performed 
IHC to stain Numb levels so comparing the human tumor with the mouse outgrowth. 
 
 
Figure 19 
IHC staining for Numb levels in human tumor samples and related xenografts. 
Two Numb deficient (Numb-) T1 and T2 together with two Numb proficient (Numb+) T3 and 
T4 were selected. Surgery biopsies were digested and the obtained MECs were xenografted 
in NOD SCID mice. 
IHC staining compares Numb levels between patient primitive tumors and the respective 
xenografts. FFPE sections were stained with Ab#21 
 
To confirm the scenario previously displayed in mouse model were the loss of Numb 
not only brought to destabilization in p53 homeostasis but even in mode of SC 
division we performed biochemical and TL analysis on xenograft derived MECs. 
We investigated whether these tumors undergo an expansion of the SC compartment, 
as a consequence of alterations of the mode of SC division composing the same 
scenario seen in mouse model.  
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As expected, the pool of Numb- tumors displayed a decrease in p53 level compared 
to Numb-proficient tumors, because of MDM2 mediated ubiquitinilation and 
consequent degradation (Shirangi et al., 2002; Xirodimas et al., 2001 Bottger et al., 
1997); p21, as p53 target gene, was found downregulated. 
Moreover the in vitro TL analysis shows the prevalence of symmetric mode in first 
mitotic division, consistent with the results obtained in Numb KO MECs in mouse 
(Tosoni Unpublished preliminary data).  
 
Numb restoration in Numb deficient human tumors 
To test whether the continuous expansion of the SC compartment in Numb- tumors 
was due to the absence of Numb, we infected tumor MECs with pLVX-Numb-DsRed 
to rescue the expression of endogenous Numb levels. The expression of Numb-
DsRed efficiently restored p53 levels as shown by Western Blot analysis and p21 level 
as well was restored (Fig. 20).   
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Figure 20 
Immunoblot. Numb re-expression in human tumor samples  
Cells obtained from digestion of human Numb deficient (Numb-) tumors (T1 and T2) were 
infected with pLVX puro Numb DsRed to rescue Numb levels in vitro. Numb proficient 
(Numb+) tumors (T3 and T4) were even infected and considered as control.  
pLVX EV infection (-), pLVX puro Numb DsRed infection (+), endogenous Numb level (black 
arrow), Numb DsRed (red arrow). 
Total cell lysates (30µg) from Numb- and Numb+ samples were immunoblotted with Ab#21 
monoclonal antibody. Anti p53 (Cell Signaling) Anti p21 (Santa Cruz Biotechnology) were 
used. GPR94 was detected as protein loading control. Numb levels in Numb rescued 
samples are indicated by red arrow, endogenous Numb levels by black arrow. 
 
Moreover we performed SFE assay to study the in vitro outcome of Numb restoration 
first of all to figure out possible consequences in SC compartment. The bar graph 
shows a ~ 2-fold decrease in SFE and mammospheres size after Numb rescue (Fig. 
21) in Numb deficient tumors.  
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Figure 21 
in vitro effects of Numb re-expression in human Numb deficient (T1 and T2, Numb-) and 
Numb proficient (T3 and T4, Numb+) samples upon pLVX Numb DsRed lentiviral infection. 
Bar graph represents Numb- and Numb+ SFE and MS size displayed in vitro (Ctrl -black 
columns).  
The same parameters were considered after Numb re-expression throughout pLVX Numb 
DsRed lentiviral infection (+Nb -white column).  
 
To verify whether Numb re-expression had influenced the mode of first mitotic 
division, which from a first investigation resulted mainly symmetric, we performed TL 
analysis on pLVX Numb DsRed infected human MECs. We observed a significant 
increase in the number of asymmetric divisions (Fig. 22) in Numb- tumor MECs 
reconstituted with exogenous Numb, while the Numb-DsRed expression did not 
affect Numb+ MECs mode of division that maintained mainly symmetric.  
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Figure 22 
Time Lapse analysis: Numb re-expression in vitro effects in human samples 
Numb deficient (Numb-) and samples were pLVX Numb DsRed infected in order to re-
express Numb levels (+Nb). Numb proficient (Numb-) samples were Numb over-expressed 
as positive control. 
pLVX-EV infection was performed on both Numb- and Numb+ as negative control (Ctr) 
+/- Numb recued Numb- and Numb+ cell 1st mitotic division mode was analyzed through 
TL imaging. 
The ratio between symmetric (grey columns) and asymmetric (red columns) events was 
quantified in the bar graph. 
 
On the base of these evidences we decided to perform in vivo experiments in order to 
investigate on possible consequences of Numb reconstitution on tumor growth. 
Numb- tumor MECs were Numb-reconstituted by lentiviral infection and xenografted 
in mouse fat pad. These MECS generated tumors that were ~2-fold smaller in size 
compared to mock-infected controls (Fig. 23). 
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Figure 23 
Numb re-expression in vivo effects in human tumor samples.  
Numb re-expressed (+Nb, pLVX Numb DsRed infected) Numb- (T1 and T2) cells were 
injected in one side breast, pLVX-EV infected (Ctr) Numb- cells were injected as negative 
control in the other side breast and let both the tumor masses develop. Numb+ (T3 and T4) 
cells were equally treated and injected as positive control.        
Bar graph quantifies the tumor size reached by these transplanted cells and compares the 
tumors originated by pLVX-EV infected cells (Ctrl) (black columns) with tumors originated 
by Numb re-expressed cells (+Nb) (white columns). 
 
Numb-overexpression on MECs through lentiviral infection had on the other hand no 
effect on tumorigenesis and did not alter the final tumor volume in Numb proficient 
samples that were comparable to mock-infected controls.  
To remove the possibility of increased apoptosis or decreased proliferation 
withstanding the decreased tumor size, we stained the tumors through IHC with KI67 
and activated Caspase-3 antibodies, but no evident differences between Numb 
deficient tumors and Numb deficient tumors reconstituted with Numb protein were 
observed (Fig. 24). 
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Figure 24 
IHC on tumors derived from Numb deficient T1 cells, and Numb re-expressed T1 cells 
(T1+Nb) cells injection. 
FFPE sections were stained for KI67 (Thermo Scientific #9106) to score the proliferation 
index. 
Consecutive sections were stained for Activated Caspase (Cleaved Caspase 3, Asp175 Cell 
Signaling #9661) to quantify the number of apoptotic events. 
OCT Frozen sections were DAPI stained and observed in red fluorescent light (560nm). 
Numb DsRed fluorescent fusion protein was detected. 
 
Collectively the results argue that even in Numb- human tumors, the lack of Numb 
expression participates in the expansion of the SC compartment leading to tumor 
growth. 
 
p53 rescue in human tumors: Nutlin-3 
Once confirmed in human tumors the trend emerged in Numb KO mouse model, 
aware of the consequences of Numb reconstitution obtained throughout our 
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experimental model based on Numb DsRed lentiviral infection, as previously done 
with Numb KO mouse MECs, we step forward with pharmacological approach by use 
of Nutlin-3 in order to restore p53 levels in Numb- human MECs. Western Blot 
analysis confirms the previous evidence of Nutlin-3 treatment efficacy in p53 rescue 
in levels and activity as witnessed by p21 levels (Fig 25). 
 
Figure 25 
Immunoblot. Human tumor samples p53 rescue via Nutlin-3 in vitro treatment 
Numb deficient (T1 and T2, Numb-) and Numb proficient (T3 and T4, Numb+) samples were 
in vitro treated with 10 µM Nutlin-3 for 24 hours (+). DMSO treatment (-) was performed 
on the same samples as negative control. 
Total cell lysates (30µg) were immunoblotted with Anti p53 (Cell Signaling) Anti p21 (Santa 
Cruz Biotechnology). GPR94 was detected as a protein loading control. 
 
Following mammosphere assay was needed to confirm Nutlin-3 treatment targeted 
action on SC compartment as previously emerged by the same experiment performed 
in Numb KO mouse model. 
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Upon Nutlin-3 treatment, Numb- MECs displayed a significant reduction in the 
number (SFE) and size of MS; above all, Nutlin-3 treatment leaded to reduction in the 
ability of MS to be propagated in vitro throughout serial passages (Fig. 26) even in 
that case suggesting a reduction in SCs compartment.  
 
 
Figure 26 
SFE assay performed in serial passages on human tumor samples upon in vitro Nutlin-3 
treatment. 
Numb deficient (Numb-) and Numb proficient (Numb+) selected samples were tested to 
score in vitro MECs SFE. The assay was performed for at least 4 passages. (Ctr -grey dots). 
The same SFE assay was performed on MECs upon in vitro 10 µM Nutlin-3 treatment for 24 
hours. The assay was performed for at least 4 passages. (Nutlin -red dots) 
 
TL analysis shows a switch from symmetric to asymmetric trend of division 
confirming a restoration of p53 activity since p53 level emerged increased in WB 
analysis (Tosoni Unpublished preliminary data). As control, Numb+ MECs SFE and 
MSs size were not affected.  
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in vitro vs. in vivo Nutlin-3 treatment in human tumors 
Numb KO mouse cells displayed a marked susceptibility to Nutlin-3 treatment as 
proofed by the previous set of experiments. The major out coming evidence was that 
Nutlin-3 treatment did target SC compartment despite not affecting tumor growth 
when administrated in vivo in mice already developing a tumor mass. 
To investigate whether Nutlin-3 moved the same mechanisms in human tumors, in 
vitro-treated Numb- MECs were xenografted in NOD SCID mouse fat pad.  
The originated tumors were smaller compared to mock-treated cells and Numb+ 
tumors (Fig. 27).  
 
Figure 27 
in vivo effects of p53 rescue via Nutlin-3 in vitro treatment on human tumor samples. 
Numb deficient (T1 and T2, Numb-) and Numb proficient (T3 and T4, Numb+) samples were 
in vitro treated with 10 µM Nutlin-3 for 24 hours (Nutl 10 µM). DMSO treatment (Ctrl) was 
performed on the same samples as negative control. 
Nutlin-3 treated Numb- cells were xenografted in one side breast, Ctrl Numb- cells were 
xenografted as negative control in the other side breast and let both the tumor masses 
develop. Numb+ (T3 and T4) cells were equally treated and injected as positive control.        
Bar graph displays the in vivo effects of p53 rescue quantifying the tumor size reached by 
xenografted cells. Here the tumors originated by Ctrl cells (black columns) together with 
tumors originated by p53 rescued cells (Nutl 10 µM) (white columns) are shown. 
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We investigated the cause of this size difference and we demonstrated that it was not 
due to Numb- MECs proliferation decrease or apoptotic rate increase, as 
demonstrated by KI67 and activated Caspase-3 IHC staining (Fig. 28). 
 
Figure 28 
IHC on tumors derived from xenograft of in vitro Nutlin-3 treated Numb deficient T1 (T1-
Nutlin) compared to DMSO treated T1 (T1-Ctr) 
FFPE sections were stained for KI67 (Thermo Scientific #9106) to score the proliferation 
index. 
Consecutive sections were stained for Activated Caspase (Cleaved Caspase 3, Asp175 Cell 
Signaling #9661) to quantify the number of apoptotic events. 
 
The results obtained with Nutlin-3 in vitro assays drove the following experiments in 
vivo. 
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As previously done in Numb KO mouse model we xenografted Numb- and Numb+ 
human cells and once a palpable lesions had formed and reached ~0.5 cm in 
diameter (Fig. 29 dashed red line), Nutlin3 was administered intraperitoneally every 3 
days for 12 days for a total of 4 treatments using a dose of 20 mg/kg. Tumors were 
let grow and interestingly in vivo drug treatment did not lead to a significant 
decrease in the final tumor size (Fig. 29).  
 
 
Figure 29 
Effects of p53 rescue via Nutlin-3 in vivo treatment on human tumor samples. 
Numb deficient (T1 and T2) cells were xenografted separately. Each sample cells were 
injected in both breasts and let the tumor mass develop up to the palpable lesion (~0.5 cm 
in diameter, dashed red line) when 20 mg/kg Nutlin-3 was injected intraperitoneally every 
3 days for 12 days  
The bar graph shows the difference between the tumor size reached by DMSO treated 
tumors (Ctrl –black column) and the Nutlin-3 treated tumors (Nutl. 10 µM –white column). 
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According to the results previously obtained on second generation Numb KO tumors 
that were in vivo treated with Nutlin-3 we explanted and reduced to MECs the human 
tumors undergone Nutlin-3 in vivo treatment. Although cells were not exposed to 
any further drug treatment, as happened in Nutlin-3 in vivo treated Numb KO 
tumors, human Numb- tumors MECs displayed a significant SFE and MS size decrease 
as emerged by in vitro mammosphere assay (Fig 30b) thus demonstrating SC target 
efficacy. Nutlin-3 in vivo treatment was even proofed by Western Blot analysis were 
Nutlin-3 treatment shows efficacy in p53 rescue both in levels and activity, as 
witnessed by p21 levels (Fig 30a). 
Thereby we tested these Numb- tumors MECs tumorigenicity in vivo by xenograft 
assay in NOD SCID mice. Nutlin-3 in vivo treated MECs grew in smaller sized tumors 
if compared to not treated cells (Fig 30c) and again, Nutlin-3 treatment did not affect 
proliferation or apoptosis in vivo as demonstrated by KI67 and Caspase-3 activated 
IHC staining.  
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Figure 30 
(a) Immunoblot. MECs obtained from Nutlin-3 in vivo treated Numb deficient (T1 and T2, 
Numb-) tumors were reduced to MECs by digestion to verify p53 rescue consequent to 
Nutlin-3 in vivo treatment (+). The immunoblot compares their p53 levels with control 
DMSO in vivo treated tumor derived MECs (-). Total cell lysates (30µg) were immunoblotted 
with Anti p53 (Cell Signaling) Anti p21 (Santa Cruz Biotechnology). GPR94 was detected as 
a protein loading control. 
(b) Left: Nutlin-3 in vivo treated Numb deficient tumor derived MECs were xenografted and 
let develop the second generation tumor. Control DMSO treated tumor derived MECs were 
xenografted at the same time. The bar graph displays the difference between second 
generation tumor sizes reached by MECs belonging to DMSO treated first generation tumor 
(Ctrl -black column). 
The white column (Nutl. 10 µM) represents the size of tumor originated from MECs 
belonging to Nutlin-3 in vivo treated first generation tumor. 
(b) Right: the second generation tumors were digested and SFE assay was performed on 
MECs obtained. 
 
As happened in mouse MECs, in vivo Nutlin-3 treatment displayed effect on SCs 
obtained from in vivo treated tumors digestion, as seen by SFE and MSs size 
reduction while TL analysis confirms this evidence on the base of their first mitotic 
division (Tosoni Unpublished preliminary data). 
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Interestingly the same result emerged by in vitro treated MECs later injected in vivo. 
Nutlin-3 appeared not efficient in in vivo treatment since no difference was displayed 
in terms of reached size between DMSO and Nutlin-3 perfused tumors. On the other 
hand Nutlin-3 treatment showed late effects on SFE and MS size of MECs obtained 
from in vivo treated tumors. Furthermore we could see Nutlin-3 effects when these in 
vivo treated samples where xenografted again to score their tumorigenic ability. The 
second generation tumor growth was impaired in Nutlin-3 previously treated sample 
as witnessed by their smaller size.  
This evidence introduces the SC compartment as the effective aim of Nutlin-3 action. 
The tumor size growth is ruled by PC expansion and cannot be affected by Nutli-3 
treatment. On the other hand the SFE reduction, seen in in vitro assays, upon Nutlin-
3 treatment confirms a reduction in SC compartment even according to second 
generation tumor size decrease. These reduction is witness of the in vivo Nutlin-3 
late effect on SC, of which tumorigenic phenotype is most likely reduced.  
These results shows that the kinetic behavior of the SC compartment in Numb- 
breast cancers phenocopies the genetically-defined SC compartment of Numb-KO 
mice, and establish that the Numb-p53 axis plays a relevant role in human mammary 
tumorigenesis, via its impact on the homeostasis of the mammary SC compartment. 
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MATERIALS AND METHODS 
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Gene Knocking Out: The Cre/loxP recombination 
system in transgenic mice 
The Cre/loxP system is useful for tissue-specific knockout of genes to investigate the 
in vivo effects of their loss. This technique can be used both to eliminate an 
endogenous gene (Knocking Out) or activate a transgene (Knocking In).  
Cre is a 38 kDa recombinase protein from bacteriophage P1. This enzyme roles site 
specific recombination between loxP sites through both intramolecular excision or 
inversion. Cre can also mediate intermolecular integration of genes. 
A loxP site (locus of X-ing over) consists of two 13 bp inverted repeats separated by 
an 8 bp asymmetric spacer region. One molecule of Cre binds per inverted repeat or 
two Cre molecules line up at one loxP site. The recombination occurs in the 
asymmetric spacer region. Those 8 bases are also responsible for the directionality of 
the site. Two loxP sequences in opposite orientation to each other invert the 
intervening piece of DNA, two sites in direct orientation dictate excision of the 
intervening DNA between the sites leaving one loxP site behind.  
Two mouse lines are required for conditional gene deletion.  
• a conventional transgenic mouse line with Cre targeted to a specific tissue or cell 
type; in our mouse, Cre activity is K5 promoter dependent, thereby activated in the 
breast and other epithelial tissues. 
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• a mouse strain that embodies a target gene (endogenous gene or transgene) 
flanked by two loxP sites in a direct orientation, the so called "floxed gene", in our 
experiment, Numb is double foxed in loxP-Numb-loxP.  
The recombination, so the excision and consequently inactivation of the target gene, 
occurs only in those tissue expressing CK5 thereby performing Cre recombinase 
activity. Hence, the target gene remains active in all cells and tissues in which Cre is 
not activated (Wagner et al., 1997) 
 
Figure 1 
The Cre/loxP recombination system in transgenic mice 
Mouse breeting between conventional K5-Cre transgenic mouse and double floxed Numb 
mouse to obtain the Numb KO mouse, lacking Numb in CK5 dependent districts. 
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 FVB/Hsd mice 
In 1966 two mouse strains, HSFS/N and HSFR/N were selected for sensitivity and 
resistance, respectively, to the action of Histamine after treatment with Bordetella 
pertussis vaccination. Later a group of mice at the eighth inbred generation of 
HSFS/N were found to carry the Fv-1b, allele for sensitivity to the B strain of Friend 
leukaemia virus. Homozygous mice were then inbred without further selection for 
histamine sensitivity and the final strain obtained was named FVB (Taketo et al, 
1991). 
This strain is slightly different from the largely used C56 strain. The microsatellite 
analysis indeed puts in evidence a difference of 145 markers between FVB/N and 
C56BL/6J strains (Neuhaus et al, 1997). 
These mice have a vigorous reproductive performance with large litters, (Taketo et al, 
1991) because of that, this prolific strain was chosen to explant considerable 
amounts of breast tissue to purify the highest number of SCs.  
 
NOD SCID IL2 R gamma-chain null 
Non-obese diabetic (NOD) strain mice were developed at Shionogi Research 
Laboratories in Aburahi, Japan by Makino et al in 1980. This strain exhibits a 
susceptibility to spontaneous development of autoimmune insulin dependent 
diabetes mellitus (IDDM) (Kikutani H, Makino S 1992) as other autoimmune 
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syndromes.  
NOD/SCID/ILR γnull strain was generated by 8 backcross matings of C57BL/6J-γnull 
mice and NOD/Shi-scid mice.  
The resulting strain is a double homozygous for the severe combined 
immunodeficiency (SCID) mutation and interleukin-2 Receptor γ (IL-2 R γ) allelic 
mutation (γ null). This strain was previously (Ito et al 2002) introduced as an excellent 
recipient mouse model for engraftment of human cells.  
Human CD34+ cells transplanted into this strain, displayed a significantly higher 
engraftment rate in NOD/SCID/ILR γnull strain than that in NOD/Shi-scid mice treated 
with anti-asialo GM1 antibody or in the β2-microglobulin–deficient NOD/LtSz-scid 
(NOD/SCID/β2mnull) mice.  
In NOD/LtSz-scid and NOD/Shi-scid mice, in order to ameliorate engraftment 
efficiency for transplanted human cells, the injection of anti-NK cell antibody before 
transplantation was used while the γnull mutation in NOD/SCID/ILR γnull confers a 
constitutive lack in NK cell activity (Ohbo et al., 1996). 
This indicate that residual NK cell activity might interfere with engraftment efficiency 
(Koyanagi 1997  Yoshino H 2000). Multiple immunological dysfunctions, including 
cytokine production capability, in addition to functional incompetence of T, B, and NK 
cells, may lead to the high engraftment levels of xenograft in NOD/SCID/γnull mice. 
According to that NOD/SCID/γnull display a severe reduction of interferon-γ (IFN-γ) 
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production from dendritic cells in the mouse spleen and even that may lead the 
comprehensive impairment of immunological functions (Ito et al 2002). 
High engraftment rate were reported since low numbers of cells, up to 1 × 102 
CD34+, could grow and differentiate in this strain underling a possible application 
even in multilineage cell differentiation. For this reason NOD/SCID/γnull mice were 
considered as superior animal recipients for xenotransplantation and were especially 
valuable for human stem cell assay (Ito et al 2002). 
 
Tissue collection and digestion 
Five weeks old female FVB/Hsd mice are used to collect both axillary and inguinal 
breasts. The sample taking must be done under sterile hood and before opening the 
carcass the fur must be carefully disinfected. 
This animal age has been chosen since from 4 to 6 weeks of life, mouse breast 
contain the highest number of SCs in a relatively small sized fat pad.  
Tissues can be stored at 4°C in sterile saline solution or PBS until the beginning of the 
preparation when the sample is minced by sterile scissors into ~1−2 mm3 pieces. 
Reduced tissue is immediately resuspended in 10 mL pre-warmed EDM and 
incubated at 37°C in a 5% CO2 humidified incubator. The digestion mixture must be 
resuspended up and down with pipette several times (~5–7) every 20–30 min to aid 
tissue dissociation until all large fragments are digested. Groups of 5 animals for a 
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total number of 20 mice are used; the equivalent amount of 5 mice tissue is totally 
digested in 4 hours.  
The digested tissue suspension is transferred in conical bottomed tubes and 
centrifuged at 80 × g for 10 min at room temperature. This step of differential 
centrifugation will allow to separate single stromal cells, mostly fibroblasts and 
endothelial cells which will remain in the supernatant (Eirew et al., 2008), from the 
epithelial portion of the mammary tissue that contains primary normal mammary 
epithelial cells (MECs) and SCs together with large clusters of tissue commonly 
referred as to “organoids”. 
The supernatant is carefully removed eliminating fat residues and stromal cells; the 
pellet is gently resuspend in10 mL DMEM plus 2 mM L -Glutamine to yield a 
homogeneous suspension. The material is filtered sequentially using cell strainers 
(BD Falcon) of decreasing pore.  
The first 100-µm cell strainer retains gross digestion residues together with fur or 
possible muscle and skin fragments. The so obtained flow through is sieved for first 
in 70-µm and than in 40-µm cell strainer. Pure organoids are retained during this 
step, while the last filtration with 20-µm syringe bound strainer eliminates the 
digestion residues such as groups of aggregated cells smaller than organoids. Pure 
MECs are so obtained in single cell suspension.  
Blood cells are typically small sized and go through all the steps of filtration. To 
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remove them an ipotonic 0.2% NaCl solution can be used for 60’ to induce a volume 
shock and to lysate red blood cells. To avoid any damage on the MECs population the 
physiological condition must be restored in cell suspension neutralizing the 0.2% 
NaCl with a 1.6% NaCl. MECs are thereby resuspended in the specific medium to allow 
the SCs growth, the Mammary Epithelial Stem Cell Medium (MESCM).  
Notwithstanding the several adopted tricks to purify MECs a certain amount of 
contaminant cells remains in the MECs suspension. To remove this fraction, rather 
than seed cells directly on non-adherent supports in order to perform the 
mammosphere assay, it is useful to place MECs on non-tissue culture treated 
supports. This environment maintains the SCs fraction in anchorage independent 
conditions while permits strong adhesive cells, such as fibroblast to weakly adhere to 
the bottom. In a short time the bulk mammary epithelial cell population will be 
deprived of contaminants and the pure MECs can be delicately collected to be seeded 
on Poly-HEMA coated plates. 
 
Enzyme Digestion Mixture (EDM) 
EDM is obtained from a solution of DMEM (Lonza) + HAM’s nutrient mixture F12 
medium (Gibco) (1:1 ratio) supplemented with 1 µ g/mL insulin (Roche), 1 µ g/mL 
Hydrocortisone (Sigma), 100 U/mL Penicillin, 100 U/mL Streptomycin and 2 mM L-
Glutamine. EDM is sterilized through a 0.2- µ m vacuum filter unit and store at 4°C 
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until needed. Immediately before use, 10 ng/mL EGF (Peprotech) 200 U/mL 
Collagenase type 1A (Sigma) and 100 U/mL Hyaluronidase (Sigma) are added. EDM 
should be prewarmed at 37°C in a water bath before adding to sample tissues.  
 
Mammary Epithelial Stem Cell Medium (MESCM) 
MEBM Basal Medium (Lonza) is supplemented with 100 U/mL Penicillin, 100 U/mL 
Streptomycin, 2 mM L -Glutamine, 5 µ g/mL Insulin, 0.5 µg/mL Hydrocortisone, 1 
U/mL Heparin (Wockhardt).  
The complete medium MESCM is obtained by adding 20 ng/mL EGF, 20 ng/mL FGF 
(Peprotech), and 2% B-27 Supplement (Gibco) immediately before use.  
B-27 is a serum-free supplement typically used in research for growth and long-term 
viability of hippocampal neurons. The selection of its inner components makes B-27 
successfully suitable even for epithelial mammary SCs research because of the 
absence of serum that would otherwise drive the in vitro SCs differentiation.  
The complete medium is filter sterilized through a 0.2- µm filter prior to adding 
complete MESCM to cells.  
 
Sphere culture Supports 
To obtain supports suitable for cell suspension culture, low adhesion plates were 
prepared using Non-Tissue culture treated flat bottomed plates (Falcon). These 
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plates were doubly coated with the inert, chemically stable, non-toxic polymer 
named Poly-HEMA (2-hydroxyethylmethylmethacrylate) (Sigma). 
A stock concentration (12%) Poly-HEMA solution is prepared by dissolving 25 g of 
Poly-HEMA crystal powder in 208 mL 95% ethanol overnight at 55°C using a rotating 
shaker. From this stock concentration, a 1:10 dilution in 95% ethanol is prepared to 
yield the Poly-HEMA working solution at a final concentration of 1.2%. Filter sterilize 
through a 0.2- µm vacuum. The second bottom plate coating must be applied only 
when the first volume of Poly-HEMA has completely dried under a sterile hood.  
 
Isolation of primary SCs from mouse breast 
This methodological approach is suitable for the isolation of pure SCs population 
from both mouse and human dissociated mammary gland (Pece et al., 2010; Cicalese 
et al., 2009). 
Tosoni et al set up this strategy relying on two key defining SCs properties, namely 
their relative quiescence and their ability to survive in anchorage independent 
conditions. SCs can indeed withstand anoikis, an apoptotic process due to anchorage 
detachment (Pece et al., 2010; Cicalese et al., 2009; Dontu et al., 2003). Bulk primary 
mammary epithelial cells were isolated from either murine or human mammary 
tissues and cultivated in MESCM in absence of adhesion, condition in which, the 
innate shape reachable by dividing cells is the sphere, thereby the so obtained 
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“mammosphere”.   
SCs compose a small fraction of the entire dissociated bulk mammary epithelial cell 
population; their low division rate allows us to track them down by staining with a 
lipophilic dye, the PKH26 (Sigma).  
PKH26 must reach a final 1:10000 ratio in the total reaction volume; PKH26 is for 
first pre diluted in a volume of PBS equal to the half of total reaction volume, this 
step avoids the cells to be stressed by pure PKH26 direct contact. Up to 107 cells are 
resuspended in an equal volume of PBS and mixed to the pre-diluted PKH26. The mix 
is incubated in the dark for 5’ at RT, the cells are collected and seeded in culture.   
PKC26 will be half-retained by the SC from the first mitotic division, while 
progressively diluted by the counterpart of progenitors cells (PC) undergoing several 
following rounds of mitosis. PKH-labelling of mammospheres was obtained using 
either the PKH26 (red epifluorescence) or the PKH2-GL (PKH488, green 
epifluorescence) dyes (Sigma), as appropriate. 
To Exploit Fluorescence-activated cell sorting (FACS), which is a specialized type of 
flow cytometry (Herzenberg, et al., 1972), we used Vantage SE flow cytometer 
(Becton&Dickinson) equipped with a 488 nm laser (Enterprise Coherent) and a band-
pass 575/26 nm optical filter (FL2 channel). An average sorting rate of 1,000 events 
per second at a sorting pressure of 20 PSI was maintained. 
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After 1 week of selective SC culture, single cell suspensions, from desaggregated 
PKH-labelled mammospheres, were sorted using a FACS assay. We were able to 
quantify the number of PKHHIGH quiescent/not dividing SC since all the other cells (PC) 
have diluted the dye (thereby PKHLOW and PKH NEG) undergoing rounds of mitosis. 
FACS thereby discriminates and collects PKHHIGH , by purifying SCs from the 1st 
generation of mammospheres we can score the starting amount of SCs in the 
mammary epithelial buck population. 
 
 
Figure 2 
FACS-distribution of PKH cell subsets in WT mammospheres 
Mammospheres desaggregated led to a heterogeneous distribution of stained cells.  PKHHIGH 
SC can be separated from PKHLOW and PKH NEG PC. 
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The cut off value considered to identify PKHHIGH region in FACS output data was 
defined according to the calculated percentage of SCs in the mammospheres 
(Cicalese et al., 2009). 
The FACS assay can be replicated for the following generations of mammospheres 
because of SC self renewing in order to see whether the SC compartment remains 
even or rather it is expanding, in our case WT PKHHIGH grew in sphere until to 3rd 
generation while PKHLOW and PKH NEG PC could not be further passaged in culture 
(Cicalese et al., 2009). 
PKH26 can be even tracked by fluorescent light beam in the deep core of the 
structure obtained by the dividing PCs. This strategy is suitable not only for normal 
mammary SCs but also for isolation of CSCs making this technique even more 
essential because of the issue of breast cancer heterogeneity that would have been 
otherwise managed with the complex SC-specific immunophenotypical marker 
approach. 
 
The mammosphere assay and SFE 
According to published data (Cicalese et al., 2009) the normal SCs spawn a sphere 
containing  ~300 cells. This structure is approximately ~100µm sized. The 
mammosphere assay consists in a precise retroactive study of SCs number relying on 
the sphere number found after a determined period of MECs culture. As previously 
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said, because of both the MESCM and the lack of adhesion, SCs proliferate to the 
detriment of MECs bulk population and the final number of sphere in suspension is 
indicative of the SCs number included in the early bulk population. 
The SFE in an index describing this ratio; its value is obtained applying the formula: 
 
(nr spheres counted/nr cells seeded) *100 
 
Considering a normal SC giving a ~300 cells sized sphere, the SFE value is ~0.3% 
Once counted, the spheres can be collected and mechanically disaggregating in a 
single cell suspension in order to count their total number to estimate the average 
sphere size applying the formula: 
 
nr cells counted/nr spheres disaggregated 
 
This assay comes useful moreover to estimate SCs self-renewing potential in vitro. 
Indeed once the SC is released from its PCs envelope that inhibited SCs mitosis, the 
SC can divide again skewing another sphere; that process can be repeated up to 3/4 
times in a normal sample until the self-renewing extinguishment. 
On the other hand, in tumor samples, as previously demonstrated (Pece et al., 2010; 
Cicalese et al., 2009), CSCs grow in number throughout the generations in vitro 
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giving an increase in SFE index and sphere size. 
In this case the mammosphere assay gives information about the starting number of 
CSCs in a sample and moreover its increase though the time. To score the cumulative 
number of sphere throughout the generations in vitro the mammosphere re-plated in 
a serial assay. 
 
Serial re-plating of mammospheres 
For serial re-plating experiments, 5,000 (N1) cells from primary dissociated 
mammospheres were plated in quadruplicate onto Poly-HEMA treated plates (24 
multiwell) and, after 6 days, dissociated as described and re-plated at the same 
density. 
This procedure was repeated through several passages of dissociation/re-plating, 
and at each passage (i) the number of spheres (Sp) and relative dissociated cells (N) 
were determined. The average number of cells that compose a sphere (sphere size, S) 
was calculated as the ratio between (N) and (Sp). 
Cumulative sphere (CS) and cell (CN) curves were respectively calculated as: 
CSi = CSi-1 · (Spi / Sp1) 
CNi = CNi-1 · (Ni / N1) 
where CSi or CNi represent respectively the values of cumulative sphere and cell 
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curves at the passage i, Spi and Ni the sphere and cell numbers counted at the 
passage i, and Sp1 and N1 the number of plated spheres and plated cells. To note 
that the passages may be seen as a time unit of 6 days. Since the sphere size was 
constant during serial passages the value of Sp1 was calculated as the ratio between 
plated cell (N1=5,000) and average sphere size (S) during all passages. The 
cumulative curves plotted in a semi-logarithmic graph appear as straight lines, thus 
suggesting they resemble an exponential curve, as expected for a cell population that 
grow or die with a constant rate during the time. The cumulative curve may be 
expressed as: 
C = C0 · GRi 
where C represents the value of the curve at the passage i, C0 the value of the curve 
at passage 0 and GR the rate by which the curve grows (if GR>1) or decreases (if 
GR<1). To verify the exponential correlation between the cumulative numbers and 
time of culture, exponential regression of the data was performed. The exponential 
curve was converted to a linear one, using logarithm properties: 
C = C0 · GRi 
log(C) = log(C0 · GRi) 
log(C) = log(C0) + log(GRi) 
log(C) = log(C0) + log(GR) · i 
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The last equation represents a linear function where log(GR) is the slope of the line 
and a linear regression (using the least squares method) can be performed to 
calculate log(GR) and then GR. (cicalese) 
 
3D-Matrigel Assay 
Cells were seeded in 4-well chamber slides (LabTek: 2000 cells/ml/well) in Matrigel 
(BD-Biosciences) overlay or embedding conditions as described by Lee et al., and 
then cultured for 15 or 20 days. The resulting outgrowths were photographed and 
analyzed. All measurements were made with ImageJ software.  
 
Time Lapse (TL) Live Imaging analysis 
The mammosphere assay allows estimating the overall presence of CSCs in a sample 
but if a deeper investigation of the dynamics at the base of this increase is needed, 
hence we exploited the TL analysis. 
The Microscope Cage Incubator (Okolab) encloses the IX81-ZDC bright 
field/fluorescent microscope station (Olympus); this system has a laser-based Z-drift 
compensator and works as a dynamic scanner. The software plans a virtual grid 
above the tissue culture well and by keeping focused more fields, it can capture at 
different time points the cells shape recording the very first mitotic division and all 
the followings. The cells viability during all the record period is guaranteed by the 
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Cage Incubator, which maintains a microenvironment as close as possible to the 
culture incubator. In that manner, by analyzing the number of cells spawn from a 
single mitotic division it is possible to evaluate weather a symmetric rather than an 
asymmetric division has taken place. Furthermore overexpressing upon infections 
factors like Numb, by tracking Numb-DsRed, it becomes possible to study its 
distribution during the SCs division. 
To keep the cells static during the recording, the single cell suspension is embedded 
in Methylcellulose-based medium (MethoCult™ Stemcell Technologies) previously 
reconstituted with with 10% mammosphere medium MESCM (see Mammary Epithelial 
Stem Cell Medium (MESCM)) containing 10-fold concentrated supplements.  
Mammospheres were desaggregated to single cell suspension, resuspended in 
MESCM at the concentration of 5,000 cells per 30 µl and added to reconstituted 
methylcellulose in a 1:10 ratio. 300 µl of methylcellulose (5,000 cells) were then 
plated in glassed bottom wells (MatTek CorporationTM) to increase imagine quality.  
 
TL statistical analysis 
The statistical analysis on TL videos was performed only on single living cells without 
considering the small groups or cells aggregates. The first and second mitotic 
divisions were considered to score the ratio between asymmetric versus symmetric 
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events occurred. Throughout TL analysis even MSs size and SFE were estimated and 
studied in relationship with the first mitotic division modality.   
 
Transplantation experiments: In vivo xenograft 
assays 
Five week-old NOD/SCID IL2R gamma-chain null female mice were used for cell 
transplantation. 
Animals were treated with Tribromoethanol (Avertin®), a popular injectable 
anesthetic; witch was delivered by intra peritoneal injection. Avertin was prepared 
resuspending 2.5 g of 2,2,2 Tribromoethanol in 5 ml of 2-methyl-2-butanol 
(amylene hydrate, tertiary amyl alcohol). This step requires o/n heating to 
approximately 40° C and stirring. The solution was diluted in 200 ml distilled water 
(neutral pH), than filtered, stored at +4° C and protect from light since the material 
becomes toxic if it degrades. 
Avertin is appropriate for short term surgical procedures, it induces anesthesia 
rapidly and provides good surgical analgesia for approximately one hour. Mice were 
injected with a size proportional volume of Avertin, (10 µl/g). (IACUC Guidelines for 
Use of Avertin Tribromoethanol (Avertin) in Mice) 
Mice abdominal skin was excised with surgical scissors and the inguinal fat pad 
exposed. To evaluate the transplanted cells MRU, the breast tissue of the 4th 
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mammary gland, which is located in low-abdominal/inguinal area. (Figure 3. Lateral 
view). The fat pad was partially removed by cutting from half line on the central 
lymph node to lateral limit (fat pad clearance).  
 
Figure 3 
Diagram of Mammary Tissue 
Left. Lateral view; in evidence cervical (1), thoracic (2,3) and abdominal (4) breasts. 
Right. Ventro-dorsal view; distribution and contiguity of mouse breasts, in evidence the 
position of cervical, pectoral and inguinal nipples.  
Adapted form The Virtual Mouse Necroscopy Comparative Medicine Branch 
 
 
Figure 4 
Macroscopic detail. 4th mammary gland undergoing transplantation 
Left: site of injection. Cells are concentrated in the nipple posterior area 
Right: Outcome of injection  
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Cells or mammospheres were were resuspended in 40 µL of a 1:1 Matrigel-PBS 
solution and injected with micro volume syringe (Hamilton). 
Mice were monitored by hand-palpation for tumor development. Tumor growth was 
measured by using a vernier caliper and applying the standard formula: tumor 
volume = (a x b2)/2. Mice were sacrificed when tumors reached a dimension of 1.5 – 
2 mm3. Tumors were explanted, weighed, and processed for formalin-fixing and 
paraffin embedding. 
The surgical removal (clearing) of the mammary fat pad was performed as reported 
(DeOme et al., 1959) since in the 4th mammary gland of a 5-week old mouse the 
mammary epithelium is concentrated in the nipple area and has not yet grown out 
beyond the mammary lymph node penetrating the bulk of the fat pad. Clearing of the 
fat pad from the nipple to the lymph node leave the bulk of the fat pad free of 
epithelium and ready to receive cells throughout transplantation. 
For the evaluation of outgrowths, fat pads were whole mounted (8 to 10 weeks after 
transplantation) and analyzed as described (DeOme et al., 1959; Sleeman et al., 
2005). 
Briefly, they were scored as negative for outgrowth if “no epithelial structures could 
be observed or if an epithelial ductal network could be seen, in which the majority of 
ductal branching had the same direction and had grown in from one edge of the fat 
pad”. They were instead scored as positive if “outgrowths could be seen to have 
	   121	  
originated from a central region of the cleared fad pad and the directionality of the 
ductal branching was different in different parts of the fat pad”. The exogenous 
epithelial reconstitution was witnessed by growing terminal ends ducts.  
 
Statistical analysis of limiting dilution transplantation 
Limiting dilution data and SC frequencies were analyzed using generalized linear 
models, as implemented in the limdil function of the “statmod" package 
(http://cran.rproject.org/web/packages/statmod/index.html) for the R computing 
environment (http://www.r-project.org/). The single hit Poisson model underling 
limiting dilution was estimated by a complementary log-log generalized linear model. 
A confidence interval was obtained for the SC frequency by computing two-sided 95% 
Wald confidence intervals. In cases of zero outgrowths, exact binomial confidence 
intervals (one-sided 95% Clopper- Pearson) were computed. Goodness of fit of the 
single-hit model was estimated by testing, using the likelihood ratio test, the null 
hypothesis that the angular coefficient equals to 1 in the linear model fitted with two 
two-parameters. The null hypothesis was not rejected (p > 0.05) for any dilution 
series (Bonnefoix et al., 1996). 
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Gene Knocking Down: ShRNA Interference. 
In vitro NUMB KD was performed throughout ShRNA (Small hairpin RNA) Interference 
using lentiviral infection. Once the vector has integrated into the host cell genome, 
the ShRNA is transcribed in the nucleus by polymerase II and III (Zhou et al., 2005). 
ShRNA exportation out of the nucleus is mediated by Exportin 5 (Yi et al., 2003). 
Thereafter, the ShRNA is processed by Dicer (Haase et al., 2005) and cleaved in one 
step generating a 19-23 nt duplex SiRNA with 2 nt 3’ overhangs and loaded into the 
RNA-induced silencing complex (RISC)(Gregory et al., 2005). While the sense strand 
is degraded by Ago2 (Matranga et al., 2005), which was previously recruited by Dicer 
itself, the antisense strand directs RISC to mRNA that has a complementary sequence. 
RISC represses the translation of the target mRNA, that is cleaved by Ago2 and 
degraded, allowing the target gene silencing. Among different PLKO Sh vector, Sh39 
was chosen as most efficient in in vitro Numb knocking down. 
 
Nutlin-3 treatment 
Nutlin-3 (Cayman Chemical #10004372) (4-[(4S,4R)-4,5-bis(4-chlorophenyl))-4,5-	  
dihydro-2-(4-methoxy-2-(1-methylethoxy)phenyl)-1H-imidazole-1-carbonyl]-2 
piperazinone (C30H30Cl2N4O4) was resuspended in DMSO to obtain a final 10 mM 
concentration. Cells were treated with a final 10µM concentration for 24 and 48 
hours. Nutlin-3 treatment was performed both in cell suspension for biochemical 
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analysis and in Methylcellulose-based medium (MethoCult™ Stemcell Technologies) 
for TL experiments. For in vivo experiments Nutlin3 was administered 
intraperitoneally at the final dose of 20 mg/kg, the in vivo treatment was repeated 
every 3 days for 12 days for total 4 treatments. Mice were sacrificed and tumour sizes 
were measured. Tumors obtained were dissociated and cells were analysed by IB, to 
verify the efficacy of the Nutlin3 treatment and then either re-transplanted 
orthotopically in mice for 3 weeks 
 
Cell lysis and protein purification 
Cells were washed in PBS and lysed in RIPA lysis buffer [50 mmol/L Tris (pH 8), 120 
mmol/L NaCl, 0.5% NP40, Phosphatase and protease inhibitors were added freshly to 
lysis and wash buffers: 20 mM Na pyrophosphate pH 7.5, 50 mM NaF, 2 mM PMSF in 
ethanol, 10mM Na vanadate, Protease Inhibitor Cocktail (Calbiochem). Cells were 
harvested directly on the plates using a cell scraper. About 300 µl of RIPA lysis 
buffer/10-cm plates and 50 µl RIPA buffer/for one well of a 6-well plate were used. 
Lysates were incubated on ice for 10 min and centrifuged at 12,000 rpm for 15 min 
at 4ºC. The supernatant was transferred to a new Eppendorf tube and protein 
concentration was measured by the Bradford assay (Biorad), following manufacturer’s 
instructions. 
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SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Gels for resolution of proteins were made from a 30%, 29.1:1 mix of 
acrylamide:bisacrylamide (Sigma). As polymerization catalysts, 10% ammonium 
persulphate (APS) and TEMED were used. 
 
Immunoblotting 
Desired amounts of proteins were loaded onto 0.75 - 1.5 mm thick polyacrylamide 
gels for electrophoresis (Biorad). Proteins were transferred in western transfer tanks 
(Biorad) to nitrocellulose (Schleicher and Schnell) in 1 x Western Transfer buffer 
(diluted in 20% methanol) at 30 V overnight, or 100 V for 1 hour for small gels and at 
70 V for 3 hours for large gels. Ponceau coloring was used to reveal the amount of 
protein transferred to the filters. Filters were blocked 1 hour (or overnight) in 5% 
milk or 5% BSA in TBS 0.1% Tween (TBS-T). After blocking, filters were incubated with 
the primary antibody, diluted in TBS-T with 5% milk or BSA, for 1 hour at room 
temperature, or overnight at 4ºC, followed by 3 washes of 5 min each in TBS-T. 
Filters were then incubated with the appropriate horseradish peroxidase (HRP)-
conjugated secondary antibody diluted in TBS-T with 5% milk or BSA for 30 min.  
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Primary antibodies 
Anti Numb antibody was furnished by "Cogentech" (Consortium for Genomic 
Technologies), a core technology facility created by IFOM and IEO.  
Anti p53 (Cell Signaling (1C12) #2524) 
Anti p21 (Santa Cruz Biotechnology (F-5) #6246) 
Anti-vinculin and anti tubulin home made produced, anti-e-cadherin (BD); anti n-
cadherin (BD); anti GPR 94 (Enzo Life Sciences (9E10)) were also used. After the 
incubation with the secondary antibody, the filter was washed 3 times in TBS-T and 
the bound secondary antibody was revealed using the ECL (enhanced 
chemiluminescence) method (Amersham). 
 
Mammary gland Whole Mount staining with Carmine 
Alum 
Carmine Alum staining was used to study the whole mount architecture in mouse 
breast. Instead of the classical histological staining, which are performed on paraffin 
embedded 3 µm thick slides, Carmine Alum is performed directly on the fixed fat 
pad. This technique is exploited to get a macroscopic overview allowing for gross 
morphological changes appreciation.  
As previously demonstrated, together with biochemical alterations, Numb loss brings 
to hyperplastic and pre-neoplastic phenotypes characterized by hyperbranching and 
enlarged primary and secondary ducts (pece 2010). To get a deeper analysis on 
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these features the classical histo-pathological approach together with immune 
histochemistry (IHC) were hence coupled with Carmine Alum staining. Carmine is a 
"semi-synthetic" intensely red dye used to stain glycogen, its use requires the use of 
a mordant, usually aluminum potassium sulfate in water and gives a nuclear stain 
(Dapson et al., 2007). 
After the surgical remove, mouse inguinal mammary gland was stretched and 
flattened on a microscope slide and immediately placed in Kahle’s fixing solution for 
a minimum of 4 hours.  
Kahle’s fix (500ml)- stored at RT 
53   ml 37% formaldehyde 
147 ml 95% EtOH 
9.8  ml glacial acetic acid 
290.2 ml dH2O 
Once fixed, aftre 70% EtOH Wash, the mammary gland is rised in distilled water since 
Carmine Alum is in aqueous solution. The staining is o/n long, it is followed by a 
growing EtOH scale washing and a final xylene bath clears the fat pad from fat 
leaving an almost transparent tissue allowing the duct analysis.   
Carmine Alum solution. 
1g Carmine (Sigma C1022) and 2.5g aluminum potassium sulfate (Sigma A7167) 
were resuspended  in 500ml dH2O and boiled for 20 min. 
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immunofluorescence 
Cells were plated on glass coverslips pre-incubated with 0.5% gelatin in PBS at 37ºC 
for 30 min. Cells were fixed in 4% paraformaldehyde (in Pipes Buffer) for 10 min, 
washed with PBS and permeabilized in PBS 0.1% Triton X-100 for 10 min at room 
temperature. To prevent non-specific binding of the antibodies, cells were incubated 
with PBS in the presence of 5% BSA for 30 min. The coverslips were incubated with 
primary antibodies diluted in PBS 0.2 % BSA.  After 1 hour of incubation at room 
temperature, coverslips were washed 3 times with PBS. Cells were then incubated for 
30 min at room temperature with the appropriate secondary antibody Cy3 
(Amersham), Alexa 488-conjugated (Molecular Probes).  
After three washes in PBS, coverslips were mounted in a 90% glycerol solution 
containing diazabicyclo-(2.2.2) octane antifade (Sigma) and examined under a wild-
field immunofluorescence microscope (Leica). Images were further processed with the 
Adobe Photoshop software (Adobe) or with Image J to merge the images of the single 
channels. 
 
Immunohistochemistry 
IHC staining was performed on both frozen and fixed tissues. After surgical explant, 
tissues are formalin fixed () for a size related period and paraffin embedded. Fresh 
tissue are frozen and covered with cryostat embedding medium (OCT). 
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3 µm thick samples slices are cut by microtome and incubated in xylene in order to 
remove paraffin. 
The slices undergo antigen retrieval from formalin and paraffin through incubation in 
99º C Antigen Unmasking Buffer for 40’. 
 
Citrate: 10 mM Sodium Citrate Buffer:  
To prepare 1 L add 2.94 g sodium citrate trisodium salt dihydrate to 1 L dH2O. 
Adjust pH to 6.0. 
 
EDTA: 1 mM EDTA:  
To prepare 1 L add 0.372 g EDTA to 1 L dH2O. Adjust pH to 8.0.  
 
Endogenous peroxidases are quenched by 3% Hydrogen Peroxide and the slice is pre-
incubated with TBST 2% normal goat serum + 2% BSA to prepare the tissue for 
primary antibody incubation. The antibody is diluted in the same solution and the 
slice incubated at RT or +4º C for an antibody affinity related period.  
Secondary HRP conjugated antibodies (DAKO) were used and the DAB chromogen 
system (DAKO) was exploited for the secondary antibody detection.     
Wash Buffer (1X TBS/0.1% Tween-20 (1X TBST) is used  
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Constructs and plasmids 
The pLVX-puro lentiviral vector (Clontech #632164) was used to generate a construct 
to overexpress Numb in mammalian cells. The human isoform 71 Numb coding 
sequence (CDS) was taken from the vector pEGFP N1-Numb, already present in the 
lab (Clontech #6085-1), Numb was extracted through digestion with EcoRI and SalI. 
The same enzymes were used to digest an expression vector (pDsRed-Monomeric-
N1 Clontech #632465) carrying DsRed coding sequence, a monomeric mutant 
derived from a tetrameric Discosoma sp. Red fluorescent protein DsRed. Numb CDS 
was kept in frame with DsRed ATG in order to obtain a fusion protein Numb-DsRed 
later retrieved with EcoRI and NotI digestion. The NotI end was reduced to a blunt end 
throughout 20’ incubation with DNA Polymerase I, Large (Klenow) Fragment. Numb-
DsRed was cloned into pLVX-puro, previously digested with EcoRI and SmaI, this last 
conferring a blunt end. T4 ligase was used for o/n ligation, all mentioned enzymes 
were New England Biolabs (NEB) products. The so obtained pLVX-Numb-DsRed was 
used to overexpress Numb and to rescue its physiological levels in Numb KO models 
in vitro analysis, while in TL analysis, it was exploited for Numb tracking. With this 
system, the expression of Numb is driven by the human cytomegalovirus immediate 
early promoter. pLVX contains a puromycin resistance gene under the control of the 
murine phosphoglycerate kinase promoter for the selection of stable transductants. 
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Basic cloning techniques 
Agarose gel electrophoresis 
DNA samples were loaded onto 0.8 - 2% agarose gels along with DNA markers. Gels 
were made in TAE buffer containing 0.3 µg/ml ethidium bromide and run at 80 V 
until the desired separation was achieved. DNA bands were visualized under a UV 
lamp. 
 
Transformation of competent cells 
Fresh competent cells (50 µl), Top10 (Invitrogen) for cloning and DNA preparation 
were thawed on ice for approximately 10 min prior to the addition of plasmid DNA. 
Cells were incubated with DNA on ice for 30 min and then subjected to a heat shock 
for 1 min at 42°C. Cells were then returned to ice for 2 min. SOC medium (300 µl) 
was then added and the cells were left at 37°C for 1 hour before plating them onto 
LB-agar plates with the appropriate antibiotic. Two plates for each reaction were 
used, one plated with 2/3 of the transformed bacterial cells and the other one with 
the rest. Plates were incubated overnight at 37°C. 
 
Minipreps 
Clones picked from individual colonies were used to inoculate 5 ml LB (containing the 
appropriate antibiotic) and grown overnight at 37°C. Bacteria cells were transferred to 
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Eppendorf tubes and pelleted for 5 min at 12,000 rpm. Minipreps were performed 
with the Plasmid DNA purification kit (Macherey-Nagel) following the manufacturer’s 
instructions. The plasmids were eluted in 50 µl nuclease free H2O. 
 
Diagnostic DNA restriction 
Between 0.5 and 5 µg DNA were digested for 2 hours at 37°C with 10 – 20 units of 
restriction enzyme (New England Biolabs). For digestion, the volume was made up 
depending on the DNA volume to 20 – 50 µl with the appropriate buffer and ddH2O. 
 
Large scale plasmid preparation 
Cells containing transfected DNA were expanded into 200 ml cultures overnight. 
Plasmid DNA was isolated from these cells using the Maxi-prep kit (Macherey Naghel) 
according to the manufacturer’s instructions. 
 
Cell transfection 
Transfections were performed using calcium phosphate or Lipofectamine® 
(Invitrogen) reagents, according to manufacturer’s instructions. Lentiviral vectors lack 
in packaging protein genes for safety reasons, because of that a co-transfection with 
third generation helper vectors carrying these genes as pMDL, pREV and pVSVG are 
needed. For lentiviral production, 60% confluent packaging 293T cells were 
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transfected with calcium phosphate. Each 15 cm diameter plate was transfected with 
45 µg lentiviral vector together with 15 µg of every packaging plasmid. DNA mix was 
added with CaCl2 dropped in bubbling 2x HBS (Hepes Buffered Saline) and diluted in 
cells medium. Transfection was performed both o/d and o/n. Once removed the 
transfection medium. Virus was produced for 24 hours directly in medium of cells to 
be infected and used immediately after collection. The medium containing the virus 
was filtered through 45 µm filters, than added with fresh growth factors and 
hexadimethrine bromide (polybrene), a cationic polymer used to increase the 
efficiency of infection. In case of Lipofectamine® transfection, 80% confluent cells 
were used. Ninety µl of Lipofectamine® was added to DNA mix, prepared in serum-
free medium using 15 µg of lentiviral vector and 5 µg each packaging vector. The 
mix was incubated at room temperature for 5 min and then diluted in a pare volume 
of serum-free medium added with 60µl of Plus Reagent provided in the kit. After 
additional 20 min incubation, the final mix was added to the transfection medium 
which was removed after 3 hours incubation. Cells were then incubated at 37°C for 
o/d and/or o/n 12 hours cycles. Forty-eight hours after infection, cells were split and 
puromycin (1 µg/ml) was added to select infected cells.  
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According to the Stem Cell Theory of Cancer, at the heart of the tumorigenic process, 
is the Stem Cell and its homeostasis. Moreover, the critical role played by genes that 
regulate the Stem Cell compartment controlling the SCs self-renewal potential, the 
number of SCs and the tumorigenic potential of SCs is of particular interest is. 
Among them, I studied the protein Numb and its role in the maintenance of the Stem 
Cell compartment with particular emphasis on the consequences of Numb loss in the 
pathogenesis of breast cancer either in Numb KO mouse models on in human breast 
tumors. 
In this thesis, I have demonstrated that the cell fate determinant Numb plays a broad 
regulatory role in mammary gland homeostasis. At the top of the mammary 
hierarchy, in the MSC compartment, Numb partitions into the daughter progeny that 
retains the SC identity and imposes an asymmetric outcome to MSC self-renewing 
divisions by the liaison of p53 activity. Selective ablation of Numb or of p53 (Cicalese 
et al. 2009), causes the symmetric division of MSCs and a geometric expansion of the 
SC compartment, due to increased frequency of symmetric divisions.  
Mechanistically, I showed that p53-signaling is attenuated in Numb-KO SCs. 
Pharmacological restoration of normal levels of p53 in Numb-null cells decreased 
lifespan and self-renewing divisions of cancer SCs (to an extent identical to that of 
the WT SCs), rescues the asymmetric replicative kinetics and reverts SC expansion 
and reduced tumor expansion in vivo, without affecting significantly the growth of 
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additional cancer cells. Thus, a Numb-p53 axis controls the homeostasis of the 
breast SC compartment; the subversion of the Numb-p53 axis is relevant to breast 
cancers. I demonstrated here that the process affected by this alteration is the mode 
of self-renewal of the breast cancer SC, which becomes skewed towards a symmetric 
pattern. Loss of Numb expression, in a mouse model, leads to immortalisation of 
SCs, also prone to the acquisition of a transformed phenotype. Similarly, in Numb-
deficient human breast cancers, the expansion of the SC compartment can be 
reverted by restoration of Numb expression or of sufficient levels of p53 activity. In 
addition, my results indicate a gradient of alterations induced by loss of Numb in the 
KO model, from aberrant morphogenesis to preneoplastic lesions to various degrees 
of aggressiveness and tumorigenicity upon orthotopic transplantation. These 
observations suggest the possible selection of additional lesions to achieve a fully 
transformed phenotype. 
My data, however, unequivocally show that the altered homeostasis of the SC 
compartment is necessary for tumorigenesis in Numb-deficient human breast 
cancers. In addition, since the effects of Numb or p53 restoration were evident only 
in Numb-deficient tumours, these tumours are addicted to the loss of the Numb-p53 
axis, supporting the notion that the expansion of the SC compartment is selected for 
as an advantage-conferring event in the natural history of these tumours. As a 
consequence, Numb- or p53-targeted therapies should constitute SC-specific 
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treatments in Numb-deficient tumours. I demonstrated the proof of mechanism for 
such an approach in orthotopic xenografts and my work represents, to my 
knowledge, the first example of such anti-cancer SC targeted therapy in human solid 
tumours. 
These data demonstrate that increased frequency of self-renewing divisions in cancer 
SCs is critical for tumor growth, and suggest that asymmetric division functions as a 
mechanism of tumor suppression in mammals. Furthermore, these findings represent 
the first direct evidence that the selective ablation of cancer SCs leads to reduced 
tumor growth, thus providing experimental support to the concept of “cancer SC-
targeted therapy”. 
 
Numb asymmetric distribution at mitosis of Stem Cell 
The Stem Cell Theory of Cancer point to the responsibility of SCs’ number in the 
tumorigenic process, since the SC in normal condition divides in asymmetric mode 
generating two daughter cells, a SC and a progenitor cell, maintaining the starting 
number of SCs. When the SC mitosis does not proceed in this order, when a SC 
divides in symmetric mode, two identical SC are generated giving enrichment in SCs 
number. 
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Here, I have demonstrated that the asymmetric distribution of Numb during the first 
SC mitosis imposes an asymmetric fate on the SC progeny. Numb segregates into the 
daughter cell that retains the SC identity.  
I obtained this evidence exploiting an in vitro lentiviral infection of purified mammary 
epithelial SCs. Bulk epithelial mammary cells were obtained through enzymatic 
digestion of 5 weeks old mouse mammary glands. We used PKH dye to stain the 
entire bulk mammary population, which upon selective culture medium, generated 
floating spheroid colonies identified as mammospheres. These structures are the 
result of SC division and their cell daughter (progenitors) proliferation. SCs 
underwent a single round of mitosis thereby the PKH amount has maintained higher 
in SC and progressively diluted in the progenitors. I purified the SCs by the use of 
FACS-Sorting analysis and once obtained the pure SCs, I used the lentiviral vector 
pLVX Numb DsRed to track Numb partition during the first SC mitosis which was 
microscopically monitored by Time Lapse (TL) video-microscopy Analysis.  
This experiment showed that the PKH retaining cell, the true SC, was the daughter 
cell inheriting Numb protein. 
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Consequences in terms of tumorigenesis of Numb-loss of function 
The presence of Numb in the SC prompted us to study the consequences of Numb 
loss in the Stem cell compartment. Throughout the Numb KO mouse model and even 
with Numb KD we obtained the selective ablation of Numb. 
Throughout macroscopical (Whole mount analysis with Carmine Alum staining) and 
microscopical (Hematoxilin/heosin) investigations, I found that Numb KO mammary 
glands displayed morphological alterations, such as hyperplasia and dysplasia. 
According to in vitro assays performed on mammary epithelial cells (MECS) obtained 
form Numb KO mammary glad digestion, the loss of Numb causes an increase of 
sphere forming efficiency (SFE) and mammosphere (MS) size in comparison with 
control counterpart. Moreover the Numb KO SCs display an immortal behavior 
compared to WT SCs. 
The entire panel of in vitro experiments performed with Numb KO SCs was repeated 
with Numb KD cells with comparable results. 
These results suggest that the loss of Numb causes the symmetric division of SCs 
and a geometric expansion of the SC compartment. In agreement with the previous 
studies (Colaluca et al., 2008) arguing the existence of a Numb-p53 axis controlling 
the homeostasis of the breast SC compartment, the loss of Numb is accompanied 
even by the decrease of p53 levels and activity confirmed by p21 levels as shown by 
Western Blot analysis. 
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Since SC are able to re-constitute the epithelial tissue structure, we transplanted 
Numb KO bulk MECs in order to quantify the SC number: MECs transplantation was 
performed at limiting dilution (from 105 to 10 cells) to score the mammary 
repopulating unit (MRU) index or the cancer initiating cell (CIC) number. We 
considered these indexes to evaluate the SC number in the starting bulk MEC 
population transplanted. In many cases the outgrowths obtained displayed ductal 
hyperplasia, severe dysplasia together with preneoplastic lesions; in a minor fraction 
of cases the cells originated tumors. We collected cells from these neoplastic samples 
(identified as KO1 and KO2) and we performed MECs transplantation at limiting 
dilution; the higher frequencies of MRU displayed by KO1 and KO2 argued a higher 
SC content in their MECs population confirming the previous hypothesis out coming 
the in vitro assays. 
 
Rescue of Numb in Numb KO cells 
On the base of the results obtained from the previous set of experiments, we decided 
to proceed investigating on the effects of Numb reconstitution in Numb null SC 
compartment throughout infection using pLVX Numb DsRed lentiviral vector.  
Western Blot analysis confirms that Numb reconstitution was efficient in promoting 
the rescue of p53 levels and activity ensuring the efficacy of our rescue model. 
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SFE assay was performed on Numb reconstituted Numb KO cells which displayed a 
reduction both in SFE and in MS size arguing a reduction in SC compartment. This 
event perhaps depends on the reversion of modality of first mitotic division, from an 
almost predominant symmetric mode of Numb KO cells to a co-existence of both 
asymmetric and symmetric trends as witnessed by TL analysis. 
Numb reconstituted Numb KO cells were transplanted in order to see whether the SC 
compartment was actually diminished, and the out came tumors were in fact smaller 
than tumors grown from Numb KO EV infected cells without any alteration in 
proliferation or apoptosis of progenitors cells.  
 
p53 restoration by the use of Nutlin-3 
The previous experiments show that Numb overexpression in Numb KO cells is 
sufficient to restore the p53 activity, to impose the asymmetric replicative kinetics of 
divisions and to revert SCs expansion. 
Together with previous demonstration (Colaluca et al., 2008) that Numb sustains p53 
stability and function by interfering with the ubiquitinating enzyme Mdm2, this result 
argues that a Numb-mediated inhibition of p53 degradation in the “stem” daughter 
cell is the most likely mechanism to account for the maintenance of the SC 
compartment. To act at the level of p53-MDM2 interaction we treated Numb KO cells 
with Nutlin-3. This drug because of its molecular conformation can interfere in p53-
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MDM2 binding by occupying the p53 site of docking in MDM2 structure. We treated 
Numb KO cells with a 10µM final concentration of Nutlin-3 and the in vitro assay 
showed a reduction in SFE and MS size arguing a reduction in SC compartment. As 
demonstrated by TL analysis the SC number reduction was caused by a switch in the 
mode of first mitotic SC mitotic division, Nutlin-3 treated Numb KO cells increasing 
the number of asymmetric mitotic events. These cells were even transplanted to 
understand whether a reduction of SC compartment could lead to in vivo effects and 
interestingly the size of tumors obtained from Nutlin-3 treated Numb KO cells 
transplantation was smaller if compared with tumors grown from untreated cells. 
Furthermore I investigated whether the results obtained from Nutlin-3 in vitro 
treatment were consistent with the in vivo experiments. I decided to inject (IP) Nutlin-
3 in mice which were developing Numb KO palpable lesions. The pharmacological 
treatment did not affect the tumor growth, which is sustained by progenitor cells 
proliferation. To confirm whether Nutlin-3 treatment was efficient rather on SC 
compartment, this first generation of tumors were reduced to MECs, examined 
through SFE assay and transplanted again to study the Nutlin-3 treatment effects on 
the growth of second generation of tumors. Nutlin-3 in vivo treatment reduced the 
SFE and MS size confirming a targeted action against SC compartment, which is 
reduced as witnessed by the second generation tumor size. Indeed tumors grown by 
	   142	  
MECs obtained from in vivo treated tumors were smaller than tumors of not treated 
mice. 
Numb KO mouse model helped us to clarify the tumorigenic mechanisms in which SC 
are involved and above all we better understood the critical role of Numb and the 
effects of its loss in terms of p53 homeostasis and SC compartment regulation. This 
data were our turning point to introduce this approach of study in human contest. 
 
From mouse to human  
According to the results obtained in mouse model and aware of the evidences 
emerged on the role of Numb, the consequences of its loss and the further effects of 
its reconstitution on p53 levels and activity rather than on SC compartment, we 
carried the strategy pursued in mouse directly in human model system. 
We screened different human tumor samples collected by IEO Anatomo-Pathology 
Unit. Tumor biopsies were xenografted in NOD SCID mice breast and let the tumor 
develop. Once the lesions were grown I compared through histological investigation 
(IHC) and biochemical analysis (Western Blot) whether the xenograft characteristics 
were representative of the human primitive counterpart. Western Blot analysis 
revealed that when Numb is lost in Numb defective tumors a concomitantly decrease 
in p53 levels and activity in seen. Thereby we sorted samples on the base of their 
Numb levels choosing for the next set of experiments two Numb negative and two 
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Numb positive samples as control. Results from in vitro SFE assay together with TL 
analysis confirmed an enrichment in SC compartment occurring in Numb negative 
samples as witnessed even by cumulative sphere number assay.  
As done in mouse model we tried to revert this phenotype by reconstituting Numb 
levels using the lentiviral infection with pLVX Numb DsRed vector. Western Blot 
confirms the efficacy of this approach showing a reconstitution of Numb levels and a 
p53 rescue in levels and activity. 
Later on, SFE assay displayed how Numb reconstitution was able to reduce the SFE 
and MS size arguing an effective action on SC compartment, then confirmed by TL 
analysis that reported an increase in asymmetric event in detriment of an almost total 
symmetric phenotype in first mitotic division after Numb reconstitution. We 
xenografted Numb reconstituted Numb negative cells and Numb negative cells as 
control in NOD SCID mice breasts and here we report a decrease in tumor volume 
consequent to Numb reconstitution and not to increased apoptosis or proliferation. 
According to our intents in finding a cure for cancer, we performed Nutlin-3 
treatment both in vitro and in vivo on previously studied human samples. Numb 
negative samples responded to Nutlin-3 treatment as reported by Western Blot 
analysis displaying p53 rescue in levels and activity. Furthermore Numb negative cells 
upon Nutlin-3 showed a reduced SFE as reported by cumulative sphere number in 
serial propagation assay arguing an effective in vitro Nutlin-3 action on SC 
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compartment. Nutlin-3 in vitro treated cells were even xenografted and we report a 
decreased growth in tumor spawned by these cells which was not dependent on 
increased apoptosis or proliferation as witnessed by IHC. 
To investigate whether Nutlin-3 acted on SC compartment rather than on progenitors 
we treated in vivo by IP injection mice which were developing palpable Numb negative 
lesions and we do not report any difference in first generation tumor growth in 
comparison with Numb positive lesions grown as control. This evidence suggests a 
Nutlin-3 directed action on SC compartment, the responsible in tumorigenesis rather 
than the progenitor since the in vivo treatment was ineffective on progenitors 
proliferation hence tumor growth. This hypothesis was confirmed by SFE assay 
performed on MECs derived from Nutlin-3 in vivo treated: the decreased SFE is proof 
of Nutlin-3 action on SC compartment. We xenografted Nutlin-3 in vivo treated 
tumor derived MECs and we report a decrease in size of tumors spawned by these 
cells. 
Taken together this last data argue an efficacy of Nutlin-3 treatment on SC 
compartment suggesting Nutlin-3 as a putative treatment suitable for CSC targeted 
therapy but at the same time not useful for arresting tumor growth since not ruled by 
SC compartment but by progenitors’ expansion. Nutlin-3 could thereby considered 
as therapy for tumor relapse, event in which the SC proliferation is for sure involved.    
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